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Abstract
Microcomputed tomography (micro-CT) is a micro-imaging modality used for small animal
imaging given its high resolution, rapid scan times and quantifiable data. When studying soft
tissues, a high-density material (contrast agent) is injected to help attenuate X-rays and provide
contrast between these structures. Creation of new contrast agents is limited by short circulation
times and localization in reticuloendothelial system (RES) organs. This thesis involves the
development of two new contrast agents, which both employ tunable, degradable, self-immolative
polymers (SIP). The first project studied a small library of poly(chelate) molecules with varying
degradation rates. The second approach was based on PEtG-poly(ethylene glycol) (PEG) diblock
copolymers that encapsulated 10 nm diameter nanoparticles. Both contrast agents were
synthesized, and the poly(chelate) system was evaluated for in vivo efficacy. Overall results
demonstrated successful prolonged vascular circulation along with excretion from the body over
time by tuning the polymer’s molar mass and degradation rate.

Keywords
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Summary for Lay Audience
Small animal models are an important tool when trying to understand human diseases. The need
to analyze these animal models non-invasively is important in long-term studies, and this can be
achieved through medical imaging methods such as microcomputed tomography (micro-CT).
When trying to image soft tissues such as blood vessels or organs with CT, their similar density
makes it difficult to distinguish different structures in the image. By introducing a material known
as a contrast agent, we can illuminate these soft tissues and organs, allowing the extraction of
otherwise unavailable information. Advances in science have aided in the emergence of
nanomedicines, medicine in the nanometer (10-9 m) size range, which have been developed for use
in CT such as polymer-coated metal nanoparticles (NPs). Polymers are most commonly found in
materials like plastics. Advances such as polymer-coated NPs continue to push boundaries, but
still see limitations in the form of poor animal survival rates, localization of heavy metal materials
and short circulation times. In this thesis, we propose two entirely different and novel contrast
agents which both rely on a special class of degradable polymer known as a self-immolative
polymer (SIP), namely poly(ethyl glyoxylate) (PEtG). Based on its non-toxic degradation
products, we hypothesized that by incorporating this degradable polymer into a) an existing
nanoparticle-based system and b) an entirely novel polymer-based system, we could influence the
route that the drugs take in leaving an animal’s body. The overall results from this research
demonstrate the preparation and successful testing of one contrast agent for blood vessel microCT imaging, and show promise for the development of a contrast agent that could (ideally) be
injected multiple times before an animal would have to be euthanized.
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Chapter 1
1

Introduction

1.1

Background

Small animal models are considered essential when studying human diseases, providing valuable
insights into cardiovascular, orthopedic, and cancer research.1-3 These small animal models are
utilized both for their rapid gestation periods and ease of genetic modifications. 4 Previously,
scientific studies were confined to the investigation of ex vivo tissues or in vitro cell studies,5 but
with the development of new technologies, a wide range of medical imaging techniques have been
introduced to provide in vivo information in preclinical research.
Medical imaging modalities such as computed tomography (CT), magnetic resonance imaging
(MRI), ultrasound imaging and positron emission tomography (PET) were initially developed for
human use and were later adapted for small animal models once challenges with spatial resolution
and imaging protocols were overcome.6 The resulting microimaging modalities used currently for
high resolution imaging (tens of microns)7 include micro-MRI,8, 9 micro-CT,7 micro-ultrasound,10,
11

and micro-PET.12

Micro-ultrasound imaging focuses on the interactions between high energy sound waves and
surrounding tissue, resulting in high spatial and temporal resolution images with a capability of
real-time imaging. However, ultrasound instrument have high user-dependent image quality,
causing issues with reproducibility of images.13 MRI is a non-ionizing imaging modality that
measures magnetic properties of tissues within strong magnetic fields. This method provides
excellent contrast, high spatial resolution (100 µm), and gives insight into a variety of information
without any radiation exposure.14 The largest disadvantages associated with micro-MRI are the
high cost and long scan times associated with high resolution images. Micro-PET imaging is a
quantitative imaging modality which involves the injection of a radioactive compound that can be
tracked throughout the body by the radiation it emits. It is administered to image and measure
biochemical and physiological processes and is recognized as a fundamental tool for biomedical
research.15, 16 While established as a powerful research tool, PET use relies on availability of
radioisotopes and is niche with respect to available procedures.
1

1.2

X-ray and CT Imaging

Radiographic imaging methods such as CT are a group of imaging modalities that use ionizing
radiation in the form of X-rays to construct images. X-rays are generated in an X-ray tube by
running a current through a filament, which ejects electrons towards a tungsten anode. As the
ejected electrons interact with the electrons of the tungsten nuclei, X-rays are generated. Due to
the inherent danger associated with radiation, scan frequency and radiation exposure should always
be kept to a minimum. X-ray imaging methods make use of different tissue densities to produce,
in the case of micro-CT, three dimensional images. These images are quantitative, and can be
produced rapidly at high resolution (tens of microns in tens of minutes). 7 X-rays can be applied
in clinical scenarios for both radiotherapy and imaging, and while radiotherapy x-ray energies can
be in the MeV range, imaging X-rays (for both CT and pre-clinical micro-CT) have energies in
the tens to hundreds of keV. Clinical CT scanners often have accelerating voltages that are higher
than most micro-CT scanners to compensate for beam hardening within patients (up to 140 kVp
for larger adults). Beam hardening is a term used to describe the loss of low-energy X-rays as they
pass through a material, which narrows an X-ray distribution, resulting in a “harder” beam. Scan
times for micro-CT are generally within tens of minutes for 50-100 µm resolution, while clinical
CT imaging takes seconds to acquire images with resolutions in the range of 500 µm to 1 mm
resolution. The associated radiation dose is heavily dependent on exposure time, and micro-CT
scans often take longer to acquire so that high resolution images have adequate signal to noise
ratios.
A challenge in radiographic imaging is that many tissues inherently possess similar densities,
requiring administration of a high-density material to enhance images that would have otherwise
been difficult to distinguish. By introducing a high-density material, known as a contrast agent,
blood vessels, organs and other structures can be “opacified” and made visible in the image.
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Figure 1.1. A) Coronal micro-CT maximum intensity projection of a mouse without contrast agent
B) Coronal micro-CT maximum intensity projection of a mouse 30 min after intravenous injection
(IV) of a nanoparticle contrast agent. (Reused with permission from reference 17. Copyright Boll
et al.).
Contrast agents are injected or ingested so that they can attenuate X-rays during CT imaging, where
attenuation refers to the absorption of X-rays. Contrast media can be chosen depending on the
procedure, as different design can lead to different behavior in the body. Attenuation is quantified
by the linear attenuation coefficient (µ), which is dependent on a material’s density/concentration
in solution (ρ), atomic number (Z), atomic mass (A) and x-ray energy (E) (Equation 1.1).

µ≈

(1.1)

The measure of attenuation in CT-imaging is the Hounsfield unit, a dimensionless, relative
measurement that standardizes linear attenuation coefficients with reference to water.

𝐻𝑈 =

(µ µ

)

µ
3

𝑥 1000

(2)

By this definition, water is 0 HU, air is -1000 HU and bone ranges from 300 – 1900 HU depending
on its location and composition.18 Thus, higher quality contrast images are achieved when the
attenuation coefficient of the contrast agent is maximized. It is important to note that the above
equations consider the x-ray spectrum used in CT imaging to be mono-energetic. In fact, a range
of energies (known as a spectrum) is produced by the x-ray tube and the HU measured is
representative of the mean attenuation coefficient.

1.2.1 Dual-Energy CT (DECT) Imaging
The attenuation coefficients of contrast agents vary with energy – decreasing with increasing
energy, except for sharp spikes in attenuation at energies just above the binding energy of the
innermost atom of the material (k-shell); this spike in attenuation coefficient is known as the “kedge”. This sharp difference in attenuation coefficient just below and above the k-edge of a contrast
material is utilized in a technique known as DECT, which involves the use of two separate photon
energy ranges (keV) to provide extra information, such as distinguishing enhanced, high contrast
regions from other innately high contrast regions like bone. Knowing how a substance behaves
when exposed to a given energy can also help determine tissue compositions via DECT. 19 Figure
1.2 illustrates a scenario where elements A and B have k-edges of 90 keV and 190 keV,
respectively. This situation is purely hypothetical given the very high k-edge of the material, and
very high accelerating voltage (200 kVp). The attenuation is plotted as a function of x-ray energy
(in keV). Four unknown substances with varying amounts of elements A and B are imaged at both
energies. This allows for element A and element B amounts in each substance to be determined by
the attenuation of the substances at each energy.

4

Figure 1.2. Illustration of a hypothetical dual-energy technique to determine material composition
is shown. (Reprinted with permission from reference 20. Copyright 2010 RSNA.)
First generation clinical DECT scanners operate at 80 and 140 kVp for humans, with an increase
to 100 and 140 kVp for newer scanners.21 As a comparison, pre-clinical dual-energy micro-CT
(DEMCT ) scanners only use tube voltages of 70 and 90 kVp when imaging animals. Considering
that most micro-CT scanners can produce x-ray energies between 30-90 keV, DEMCT is difficult
with materials that have k-edges near the bounds of this range as it relies on the produced X-rays
to be above and below the k-edge energies. Therefore the best attenuating material for DEMCT
would have a k-edge near the average energies used in imaging (50-60 keV).
While there are available pre-clinical in vivo contrast agents, the use of new materials and
optimization of new designs can result in better animal modelling, especially if these contrast
media are translatable to DEMCT. If a suitable vascular contrast agent is injected intravenously,
ischemic tissues can potentially be identified, and angiogenesis reliably tracked to study
revascularization therapies.22,

23

If utilized specifically in DEMCT, smaller, less enhanced

structures could additionally be tracked. This tracking would ultimately require a vascular contrast
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agent that can escape rapid clearance while enhancing image contrast by using a high concentration
of the attenuating material, with a k-edge suitable for DECT.
Given the rapid scan times and quantifiable data that can be extracted from CT and micro-CT
imaging, it has been a consistent method of imaging clinical patients and small animals alike. 19, 2426

Of utmost importance in small animal studies is the ability to conduct studies over an extended

period of time (longitudinal) to avoid the need to euthanize the animals. In micro-CT this can often
require multiple administrations of a contrast agent, 27 and vascular contrast agents can localize in
clearance organs due to their chemical modifications that allow them to satisfy extended
circulation time requirements (~1 hr).28-30 This localization can introduce potential toxicity and/or
affect the quality of images produced over the course of a study. The remainder of this introduction
serves as a basis for understanding the chemical and imaging background involved with
synthesizing new contrast agents, before discussing the research that was conducted by our group
to synthesize and further optimize new contrast agent formulations.

1.3

Contrast Agents

Iodine is the most commonly employed element in CT contrast agents. With an atomic number of
53 and its k-edge occurring at 33.2 keV, it can provide high contrast at low energies. When imaging
humans, contrast agents are typically based on iodine,26 and are removed from the body after
several minutes via the kidneys. As an example, Bayer Healthcare manufactures a commercial
iodinated contrast agent known as iopromide, which is clinically approved for a range of intraarterial and IV imaging. Iopromide is a non-ionic x-ray contrast agent featuring a single iodinated
ring structure.26 Bracco also has a clinically available contrast agent known as iopamidol, which
can be manufactured at large scales from commercially available materials (Figure 1.3), and can
be used for angiography of the cardiovascular system among other uses. 26
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Figure 1.3. Synthesis of iopamidol from commercially available materials. (Reproduced with
permission from reference 26. Copyright 2013 American Chemical Society.)
As previously noted, micro-CT scans of live animals can take tens of minutes, and for vascular
imaging, a contrast agent is required to stay in blood vessels for the duration of the imaging. Due
to small animals having rapid metabolism as compared to humans, contrast agents must be able to
sufficiently evade clearance from the vasculature to produce acceptable images.
Foreign objects present in the vasculature of animals are typically cleared by the
reticuloendothelial system (RES) through a process known as phagocytosis. The RES is comprised
of phagocytic cells found in circulation and tissues, such as macrophages in the liver and spleen.
The process of phagocytosis involves cells engulfing large particles before further attempts at
breaking the particle down. To limit phagocytosis by the RES, PEGylation, where a coating of a
polymer called poly(ethylene glycol) (PEG) is applied, can be performed. 7 PEGylation often
extends the amount of time a material stays in the body before being detected by the RES. Polymer
use in contrast media can be generalized into two cases: acting as a means of stitching high contrast
molecules together or coating a high contrast material (Figure 1.4). This functionalization often
7

extends circulation times in the blood, and contrast media that can stay in the vasculature for
prolonged periods of time are referred to as “blood pool” contrast agents.

Figure 1.4. Visual representation of different types of contrast agents, where the red section is the
high-density attenuating material, and the black sections are polymers. The left illustrates a
polymeric molecule, and the right illustrates a nanoparticle that has been coated with the polymer.
There already exist several micro-CT contrast agents for in vivo imaging of small animals.31, 32
With the emergence of nanotechnology, contrast agents containing nanoparticles (NPs) with a
diameter > 10 nm have been synthesized for imaging, with a size suitable to avoid immediate renal
clearance.33 Fenestra VC and LC (ART Advanced Research Technologies Inc. Saint-Laurent,
Quebec, Canada) are two commercially available iodine-based blood pool contrast agents for use
in pre-clinical research. These agents comprise iodinated triglycerides in a sub-micron oil-in-water
lipid emulsion, which results in stable molecules under 200 nm in diameter and containing 50
mg/mL of iodine.25 Fenestra VC (Figure 1.5) has been shown to stay in the blood pool for several
hours, with slow clearance through the hepatobiliary organs, showing promise for time course
imaging post injection,34 while Fenestra VC has been utilized for tumor imaging22, 35 and has
shown increased contrast compared to a commercial agent, Isovue-370 (iopamidol).
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Figure 1.5. 1,3-Bis-[7-(3-amino-2,4,6-triiodophenyl)-heptanoyl]-2-oleoyl glycerol (DHOG)iodinated triglyceride in Fenestra VC.36 No permissions required.
Another example of an iodine-based blood contrast agent is eXia 160 XL, which contains
160 mg/mL of iodine. eXia 160XL, unlike Fenestra VC and LC, is a water soluble, polydisperse,
colloidal contrast.31, 37 While both Fenestra VC and LC contrast media enhance images, they still
provide low overall contrast due to low metal loading (50 mg/mL of iodine for VC). Iodine has
a low atomic number when compared to other contrast media materials, and the low k-edge of
iodine (33.2 keV) makes producing X-rays below the k-edge difficult if it were to be used DEMCT.
This is due to the inherent beam hardening that occurs during X-ray generation, as most CT
scanners will filter low energy X-rays automatically.
New contrast agents in the form of gold NPs have been developed (AuroVist 15nm, 200 mg/ml of
gold), which can provide higher contrast as gold has a higher atomic number than iodine. 27
AuroVist’s high metal concentration contributes to its excellent contrast, approximately 1800 HU
for the 200 mg/mL dosage. Hainfeld et al. were able to concentrate Aurovist to 600 mg/mL for
super high contrast, and the only animal viability problems that were encountered were associated
with the volume of contrast media that animals could take.38 While using gold provides high
contrast, it has a k-edge of 80.7 keV, which lies within the higher regime of X-ray energies. Given
that the average energy range of micro-CT scanners is 30–90 keV, using gold for specialized
techniques such as DEMCT would be difficult. DEMCT requires an excess of X-rays below and
above the k-edge, and there would be a smaller proportion of high energy X-rays above the k-edge
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of gold. To develop better contrast agents, a material needs to be chosen that has a k-edge within
the average energy range of micro-CT scanners but should also show promise for specialized
techniques such as DEMCT. This would be achievable with a k-edge that lies closer to the middle
of the average energy range (30–90 keV).

1.3.1 Lanthanide-based Contrast Agents
Lanthanide metals, a group of 15 metals with atomic numbers 57 through 71, possess special
properties within the field of imaging, and can provide higher contrast than iodine due to their
higher atomic numbers (µ ∝ Z4, equation 1.1). Lanthanides such as gadolinium or erbium have kedges that lie within the average energies used for micro-CT imaging (50-60 keV). This feature
can enable optimized performance in general micro-CT and DEMCT by being in a region where
there is a large excess of X-rays above and below the k-edge of the metal. 39 A relationship exists
where scan energy increases have an associated decrease in image quality, and while this trend is
observed with iodine, it doesn’t occur with gadolinium, providing a potential to reduce exposure
times and subsequent radiation exposure to animals.40
Gadolinium was used for clinical MRI contrast agents in the form of metal chelates such as Ablavar
and Omniscan.41 Chelates are a compounds that contain a molecule covalently bound to central
metal ion with 2 or more separate coordinate bonds. Its use within the MRI field is attributed to its
unique

magnetic

properties.26

The

most

basic

form

of

these

chelates,

Gd-

diethylenetriaminepentacetate (Gd-DTPA) has also been used for CT imaging. However, a
drawback when translating these contrast agents between imaging modalities is that they suffer
from too short circulation times for vascular micro-CT imaging, and when these circulation issues
can be over-come, the contrast media is often limited by low metal concentration. 42 Concentration
and attenuation in CT are linearly proportional, requiring vastly more metal than is needed for
MRI, which can require 10-100 times lower concentration. This limitation was observed in
previous work where the chelated derivative of diethylenetriaminepentaacetic acid (DTPA) and
Gd(III) on a cross-linked polymer nanogel was used for mouse vessel imaging. While the
synthesized molecule produced desirable results for MRI, such as increased circulation time and
enhanced contrast, the metal loading was still too low for micro-CT. This nanogel featured
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approximately 59 µg Gd/mg of gel, much lower than any vascular CT or micro-CT contrast agents
(compared to mg Gd/mg loading in CT agents), and to increase this to an amount suitable for any
type of CT would mean unrealistic volumes of the nanogel. 43-45 Lanthanide NPs have been
incorporated into contrast agents in the form of NaLnF4 (where Ln can be a single or codoped
lanthanide) (Figure 1.6),46,

47

and these agents have often been exploited for their photon

upconversion abilities. The largest challenge for using these NPs in blood vessels at high
concentrations is their surface stabilization via hydrophobic ligands. These hydrophobic ligands
induce aggregation and prevent colloidal dispersion in water. Therefore, a means of suspending
these particles at high concentrations in aqueous solution must be achieved to make them useful
for micro-CT.

Figure 1.6. Transmission electron microscopy (TEM) image of oleate coated NaGdF 4 NPs (Left)
and polymer encapsulated NP assemblies (Right). These images represent unpublished work
conducted during a summer research project.
Both chelate-based and nanoparticle-based lanthanide contrast agents still require improved
polymer systems to work well in CT imaging. Polymers are molecules consisting of repeating units
– monomers – that can be tuned in terms of their length, monomer size, and shape to meet material
property requirements. Chelates can increase their circulation time by being stitched together onto
a single, long polymer backbone48 while hydrophobically coated NPs can be stabilized in water
through optimized polymer systems.28, 29
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1.4

Polymers for CT Contrast Agents

Of interest in emerging research are biodegradable polymers, which have been commonly
employed as degradable plastics, and in medical applications such as tissue engineering scaffolds,
sutures, and drug delivery systems.49-52 Of the many biodegradable polymers, there are several that
have been most widely used. For example poly(lactic acid) (PLA), is a biodegradable polymer that
has been extensively investigated in medical applications. 53, 54 It can often be found in tissue
engineering scaffolds due to its ease of synthesis and capability to be 3-D printed. 55 Poly(εcaprolactone) (PCL) is another example of a biodegradable polymer that has been widely used for
drug delivery and tissue engineering.54,

56

Additionally, by conjugating different polymers

together, researchers have created new molecules such as poly(propylene glycol) (PPG)-PEG
copolymers for biomedical applications.57
PEG is a particularly important polymer, that as previously stated, can decrease phagocytosis by
the reticuloendothelial system, “masking” exogenous materials from the body’s immune response.
This inert behavior in the body has led to its extensive use in medicine and biomedical research.
PEG can be used clinically as a laxative in the form of Miralax (Bayer Healthcare, PEG 3350
g/mol),58, 59 prescribed for chronic constipation, but it can also be used for drug delivery, imparting
a prolonged plasma half-life (~10 hr in mice) when synthesized with molecular weights higher
than 40,000 g/mol.56 While PEG is a common excipient in medicine, it can be associated with
allergic reactions and should be administered with knowledge of existing allergies. 60 Previous
work conducted by our groups utilized polymer coated NPs as vascular micro-CT contrast agents.
The polymers investigated for NP encapsulation included PEG-PPG triblock copolymers, PEGPCL, and PEG-PLA diblock copolymers.28 Figure 1.7 illustrates some of the repeat-unit structures
of these biocompatible or bioinert (PEG) polymers.

Figure 1.7 Single repeat units of polymers commonly used in medicine
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1.5

Polymer-Nanoparticle Contrast Agents

Polymeric-nanoparticle contrast agents with a range of elements, such as iodinated polymer NPs,
have been synthesized for pre-clinical micro-CT. Aviv et al. synthesized such iodinated NPs with
29 ± 6 nm dry diameter by emulsion polymerization of 2-methacryloyloxyethyl(2,3,5triiodobenzoate) (MAOETIB), with a small fraction of glycidyl methacrylate (GMA). These
poly(MAOETIB-GMA) particles resulted in favorable contrast enhancement of the blood pool for
30 minutes before localizing in the spleen and liver due to uptake by the reticuloendothelial
system.24 Higher atomic number metals with better attenuation are ideal, and as a result researchers
have continued to explore different metal nanoparticles. Heavier metal NPs such bismuth
nanocrystals have been used in NP based contrasts agent due to bismuth’s high atomic number (Z
= 83), its low cost, and high supply. Poly(D,L-lactic-co-glycolic acid) (PLGA, an FDA approved
polymer) encapsulated bismuth NPs were synthesized for micro-CT and fluorescence imaging,
and only mild toxicity was reported for the bismuth particles. While the ex vivo results showed an
increase in contrast, concentration values related to bismuth are double the injected amount,
showing a tendency to aggregate or precipitate.61 This colloidal instability is not ideal, and while
bismuth would display higher contrast than an element such as iodine or gold due to having a
higher atomic number, it has an even higher k-edge than gold (90.5 keV), putting it above the
energy range of X-rays produced by micro-CT (90 keV).
Tantalum oxide (TaOx) NPs have been synthesized with varying degrees of hydrophilicity to be
used as micro-CT contrast agents.62 By altering reagent quantities during synthesis, the authors
were able to alter the hydrophobic/hydrophilic nature of the nanocrystals. Tantalum (Z = 73) has
a k-edge near gadolinium (67 keV), which lies within clinical and micro-CT energy ranges and
allows for its application in DECT.63 The major difference between gadolinium and tantalum is
the widespread use and vast applications of gadolinium. In their study, Chakravarty et al.
intravenously injected bare, highly hydrophilic nanocrystals which showed prolonged circulation
(~3 hr.) before accumulation in RES organs. TaOx crystals synthesized as hydrophobic or partially
hydrophilic were encapsulated within PLGA and mesoporous silica NPs respectively and these
formulations showed promise for targeted imaging as well as for drug delivery vehicles. While the
work performed did increase image contrast, it was visibly limited in micro-CT images with no
HU values reported, and biocompatibility testing used very low volumes of the contrast media. 62
13

Lanthanide NPs of the structure NaLnF4 are the most approachable in terms of synthesis, and are
coated with a ligand called oleate (deprotonated oleic acid). Oleic acid is a long, straight chain,
monounsaturated fatty acid, found abundantly in foods such as olive oil, and has been shown in
lab to work synergistically with breast cancer treatments, proving its low toxicity. 64 The limitation
with the oleate coating on the NPs is that oleate is hydrophobic, therefore requiring an additional
means to suspend the NPs in water. Previous groups have used diblock copolymers to enable
aqueous suspension of these NPs,65,

66

or polyethyleneimine to successfully stabilize and

subcutaneously inject the NPs for upconversion luminescence imaging. 47 Yet, only our group and
one other have previously synthesized a long-circulating lanthanide NP contrast agent formulation
for micro-CT.28, 67 Attempts were made to achieve this using a DPSE-PEG to encapsulate NaYbF 4
NPs codoped with gadolinium.67 This work showed suitable contrast enhancement and prolonged
circulation, with a metal content of 70 mg of Yb/mL. Unfortunately, only one rat was imaged, and
biocompatibility injections were performed on a second rat with an unspecified dosage. Our work
used amphiphilic block copolymers such as PEG-PLA, PEG-PCL, and PEG-PPG to encapsulate
the oleate-coated nanoparticles. NPs were encapsulated by nanoprecipitation and the polymer
chain lengths and encapsulation ratios (polymer:NP) were altered to optimize the final formulation
to be used for injections (Figure 1.8). The assemblies of polymer-coated nanoparticles were stable
upon redispersion in water, and the PEG successfully allowed for evasion of an immune response,
as shown by the subcutaneous injections. While the PEG adequately masked the contrast agent
from the immune system, polymers such as PLA and PCL don’t degrade rapidly, causing the
assemblies to degrade too slowly for adequate contrast agent excretion. 68, 69

14

Figure 1.8. Contrast agent preparation and injection. (Reprinted with permission from reference
28. Copyright 2018 American Chemical Society.)
The imaging results for the PEG-PLA coated NPs showed a blood pool contrast increase of +250
HU when imaging after the injection of contrast agent formulations containing 100 mg/mL of
erbium. While the contrast agent exhibited long circulation times ideal for micro-CT, inadequate
viability of the studied animals suggested a need for improvement. The low survival of injected
animals was likely caused by the slow clearance of the NPs from the hepatobiliary clearance organs
(liver, spleen), or to inherent contrast agent cytotoxicity. The NPs used in this contrast agent were
>30 nm in diameter, and a reduction to 10 nm or less could potentially result in lower toxicity by
enabling NP clearance via the kidneys.33 Supplementing smaller nanoparticles with a more
controllably degradable design could help further encourage clearance of the contrast agent.
Therefore, it is of interest to investigate systems that can be broken down into smaller components
for enhanced elimination from the body. This concept could also be of interest when trying to
stitch together metal chelate molecules to extend circulation time before degrading into small
molecules.

1.6

Metal Chelates for Imaging

Metal chelates have a broad range of uses in medicine, and within the field of medical imaging.
The most common use of these chelates in imaging research is in contrast media. 41 Gadolinium
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chelates are widely used as MRI contrast agents, with the structures determining the metal binding
affinities, kinetic stabilities, and the relaxivities of the agents, which are a measure of their ability
to alter the relaxation time of protons in water.

Figure 1.9. Commercially available gadolinium based MCP contrast agents.
The major chemical differences between the different chelates are their ligands/chelators overall
charges and structures.41, 70 The term “ionicity” refers to the overall charge of the chelate complex.
As shown in Figure 1.9, non-ionic chelators include ProHance (gadoteridol, Gd-HP-DO3A),
Optimark (gadoversatamide, Gd-DTPA-BMEA), Omniscan (gadodiamide, Gd-DTPA-BMA) and
Gadovist (gadobutrol, Gd-DO3A-butrol, not shown). 71 Ionic chelators, those carrying non-neutral
charges, include MultiHance (gadobenate dimeglumine, Gd-BOPTA 2-), Magnevist (gadopentetate
dimeglumine, Gd-DTPA2-), Dotarem (gadoterate meglumine, Gd-DOTA-1), as well as Ablavar
(gadofosveset, MS-325).70, 72-74 Meglumine and dimeglumine are used as excipients for the ionic
compounds. Ligands such as DTPA and DTPA-BMA are similar structurally, but the substitution
of two acid groups for methyl amides results in a difference in both chelate stability and overall
ionicity. The main difference in performance for these Gd-chelates stems from the structure of the
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chelator molecule. Ligands such as 2,2′,2′′,2′′′-(1,4,7,10-tetraazacyclododecane-1,4,7,10tetrayl)tetraacetic acid (DOTA) are macrocyclic molecules, where macrocyclic refers to a cagelike cyclic shape that traps metal ions. In contrast, ligands such as DTPA are referred to as linear
due to having a straight, linear conformation that “wraps” around metal ions when binding to them.
Currently, linear contrast agents are banned in Europe, and while the FDA allows use under certain
conditions, many previously commercially available linear Gd-chelate contrast media are no
longer sold. For the ban, this includes Omniscan (IV), Optimark (IV) and Magnevist (IV). Both
Magnevist and Ablavar have also been discontinued as a result of side-effects and poor sales.
While the mentioned chelates are clinically available for use, it is worth noting that there are still
some adverse effects that can occur, that depend on ionicity and ligand structure. In ascending
order of frequency, allergic reactions have been documented when using non-ionic linear, ionic
linear and non-ionic macrocyclic chelates.72 This effect is important to acknowledge as immune
responses in animals are often evaluated on a standard of cytotoxicity rather than individual
allergic predispositions. For example, DTPA elicits fewer adverse reactions than non-ionic
macrocyclic chelates. If modified so that the DTPA-metal chelate is neutrally charged (such as
with DTPA-BMA), there would be a theoretical decrease in these reactions. 72 With this said, it has
been reported that a change in a single coordination atom could result in order-of-magnitude
differences in chelation stability.75
A commonly cited concern with contrast media based on metal chelates is the possible
development of nephrogenic systemic fibrosis (NSF), a cutaneous disorder that results in skin
induration, thickening and hyperpigmentation.76 The proposed mechanism for NSF is the
transmetallation of the chelate, where free Gd3+ ions are released in exchange for endogenous
metal ions such as Zn2+, Cu2+ or Ca2+, before binding to human tissue.77, 78 High transmetallation
risk is linked to extended exposure to chelate contrast media, and therefore clearance immediately
following imaging is of the utmost importance. Claims that NSF is only a concern for renalimpaired patients have been substantiated,79, 80 such that this problem isn’t considered valid for
healthy subjects. However, transmetallation should still be monitored to ensure high animal
viability. A trend exists, where linear, non-ionic chelates are at higher risk for transmetallation
than their ionic counterparts, with macrocyclic chelates carrying the lowest risk. 30 This shows the
17

importance of balancing the risks of allergic reaction versus transmetallation due to their opposing
trends.
When compared with other ligands, DTPA is among the cheapest and easiest to obtain, and is
easily modifiable by reacting one of its five carboxylic acid groups with an amine. If one were to
create a new chelate-based contrast agent, DTPA would be an excellent choice for modification
and proof of concept before moving to other more costly chelates. However, all of the above
chelate contrast agents suffer from having far too short circulation times (with exception to
Ablavar, which is made for vessel imaging). To increase the circulation times, larger molecular
weights or PEGylation can be integrated into the design. 48, 81 A method being utilized currently is
the creation of poly(chelate)-based contrast agents.

1.6.1 Poly(chelate) Contrast Agents
Where a metal chelator (such as DTPA) is a single molecule, poly(chelate) contrast media can be
described as multiple metal-chelate molecules being conjugated together (Figure 1.10).

Figure 1.10. Visual representation of a standard metal chelating molecule and its larger
poly(chelate) counterpart. The red triangles represent the chelated metal, and the blue shape a
metal chelate.
The incorporation of many chelate molecules on a single long chain could drastically increase
metal loading (per molecule), and the accompanying increase in molecular weight can theoretically
increase the circulation time to a suitable length for CT imaging. This effect was shown where a
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series of Gd-DTPA-PEG diamines ranging in molar mass from 10,800 g/mol to 83,400 g/mol were
synthesized for imaging and a linear relationship between molar mass and blood clearance halflife was found.81 Linear Gd-DTPA-PEG polymers showed blood pool retention times over 60
minutes when the polymer molar mass was larger than 20,000 g/mol. Within the same study, a
decrease in viscosity was noted when the chelate was attached as a branch rather than as an
alternating block within the backbone.81 This polymeric design also increased the relaxivity and
consequently sensitivity of the contrast agent, resulting in low concentrations of the contrast media
being needed for MRI. It is unclear whether the molecule in this work could be concentrated
sufficiently for vascular micro-CT imaging, but the correlation of decreased viscosity with an
increasingly branched globular structure is important for translation to micro-CT imaging.
While the increase in polymer length (and subsequently circulation time) has important
implications for image quality, the extended half-life of polymeric chelate contrast media could
result in more instances of transmetallation. To overcome the risks associated with extended
exposure, researchers have turned to incorporating degradable components into the main backbone
of these polymeric chelates. For example, Lu et al. developed several macromolecular Gd(III)
complexes to increase contrast media molecular weight and contrast enhancement of MRI images,
such as poly(L-glutamic acid) Gd(III)-DOTA conjugates with degradable spacers. These spacers
react with endogenous thiols to release the chelate derivatives (Figure 1.11). 82 The agent provided
significant contrast enhancement in MRI one-hour post-injection and the signal intensity increased
in the bladder in a manner comparable to a small molecule clinical contrast agent. This result
suggests the accumulation of Gd(III) chelate derivates in the bladder via renal filtration. While
further evaluation of these degradable materials is ongoing, this work is a clear demonstration that
the linking of chelates to polymers can extend their circulation time, possibly enough for microCT imaging. It also proves that the incorporation of a degradable component allows for small
chelate derivates to be safely excreted post-breakdown. If a polymeric chelate contrast agent was
developed such that it degrades and is excreted safely while being able to sustain low viscosities
at high concentrations, it would be a suitable candidate for micro-CT imaging.
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Figure 1.11. Release of Gd(III)-DOTA from the conjugate by cysteine. (Reproduced with
permission from reference 82. Copyright 2003 American Chemical Society.)

1.7

Self Immolative Polymers (SIPs)

While most biocompatible polymers exhibit gradual degradation in vivo, polymers can be
developed such that they respond to specific stimuli. These stimuli responsive polymers (SRP) can
respond to light, change in pH, or other stimuli, and upon exposure to this stimulus, can undergo
cleavage and consequent polymer degradation (Figure 1.12).

a)

c)

b)

Figure 1.12. Illustration of the effects of stimuli on: (a) Non-degradable SRP (b) Entirely
degradable SRP (c) SIP
Stimuli-responsive polymer degradation behavior can typically be classified into one of three
categories. Non-degradable SRPs don’t degrade over time, regardless of stimulus, and they instead
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undergo material property and/or function changes following application of the stimulus. Entirely
degradable SRPs undergo depolymerization post stimulus exposure and have been used in systems
for drug delivery or tissue engineering,83-85 but they suffer from requiring multiple stimuli events
to completely degrade.86 To address challenges associated with SRP tunability and degradation
speeds, SIPs were created to amplify degradation in response to external stimuli. SIPs are special
materials, defined by their ability to undergo depolymerization of the polymeric backbone from
end-to-end after a single cleavage of a stimuli-responsive end-cap. They possess qualities of
stimuli-responsive and degradable polymers but benefit from tunability stemming from
changeable end-caps. This tunability allows for a vast variety of SIPs responsive to different
stimuli to be synthesized.
Poly(benzyl ether)s (PBE) have been synthesized as an SIP backbone, 87 exhibiting a degradation
rate that is dependent on the polarity of the solvent. When these SIPs depolymerize, they do so via
continuous elimination reactions (Figure 1.13). Cationic ammonium groups have been added to
these PBEs, resulting in excellent antimicrobial activity alongside controllable degradation
behavior.88 After degrading, the products still retain antibacterial properties comparable to the
parent polymer, but a distinct decrease in hemolytic (red blood cell) toxicity. While an excellent
proof-of-concept study, the authors noted that the highly hydrophobic nature of the PBE backbone
makes biomedical applications scarce, and that PEGylation could overcome these issues. Other
than as an antimicrobial agent, PBE-based SIPs have been investigated as adhesives and as
recyclable plastics.89, 90

Figure 1.13. Chemical structure and depolymerization of stimuli-responsive end-capped PBEs.
(Reproduced with permission from reference 87. Copyright 2013 American Chemical Society)
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Poly(carbamate)s SIPs depolymerize by alternating elimination and cyclization reactions, and
were reported by the Shabat group in 2008.91 They were synthesized by a condensation-type
polymerization reaction of an activated monomer derived from 4-hydroxylbenzyl alcohol and
N,N’-dimethylethylenediamine. Tert-butyloxylcarbonyl (BOC) protected monomer was used as
an initial end-cap, and the molecule displayed relatively slow depolymerization, with the backbone
requiring several days for complete degradation. Conversion of an amino group to an oxygen on
the N,N’-dimethylethylenediamine resulted in a carbonate backbone, and a subsequent increase in
depolymerization.92 An additional replacement of an amino group with a thiol group to provide a
better nucleophile resulted in a complete degradation time of 1-2 h. However, SIPs such as
polycarbamates or PBEs generally involve a release of toxic degradation products, motivating a
need for less toxic SIPs.93
Another important category of SIPs are polyacetals, such as poly(phthalaldehyde) (PPA) and
poly(glyoxylate) (PG) derivatives. Polyacetal SIPs degrade into their original monomers, unlike
the two former categories (cyclization and elimination). Their degradation occurs due to their low
ceiling temperatures (Tc), which is a trait defined as the temperature where depolymerization and
polymerization rates are equal. Most commercially available polymers have Tc values well above
room temperature, resulting in stable materials for daily use. For example, the simple polyacetal
polyformaldehyde has a Tc of ~120 oC in its uncapped form, but its Tc increases to >200 oC when
end-capped.94 Uncapped PPA and PG have Tc values of 40 oC and 30 oC respectively, and these
low ceiling temperatures mean that uncapped, these polyacetals undergo rapid depolymerization
at room temperature.95,

96

This can be explained by the abundance of polymer during

polymerization reactions pushing the equilibrium towards depolymerization in-situ.

1.7.1 Polyglyoxylates
Polyglyoxylates are a promising class of SIPs that have been synthesized, including for example
poly(methyl glyoxylate) (PMeG)95 and poly(ethyl glyoxylate) (PEtG).97 These polyacetals have
low ceiling temperatures that cause rapid depolymerization at room temperature, but this instability
can be controlled by the introduction of end-caps.95 This stabilization was shown when Burel et
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al. introduced isocyanate end-caps for PEtG that allowed polymer stability up to 150 oC.97 The
Gillies group introduced polyglyoxylates as new versatile class of SIPs by introducing a wide
range of tunable end-caps,98 such as a UV light sensitive end-cap (6-nitroveratryl chloroformate).
Upon exposure to UV light, the PEtG spontaneously depolymerized into starting monomers
(Figure 1.14).

Figure 1.14. Degradation mechanism of polyglyoxylates. Further hydrolysis produces the
respective alcohol. (Reproduced with permission from reference 98. Copyright 2014 American
Chemical Society.)
PEtG shows three main advantages when compared to other SIPs. First, the ethyl glyoxylate
monomer is available readily at a large scale, and can be prepared via step-wise oxidation of
acetaldehyde, which can be obtained from both bioethanol and petroleum feed stocks. 99 Second, it
was shown that PEtG degradation products were not toxic in plant and animal models, providing
a potential for use in biological applications. 100 PEtG and PMeG undergo end-to-end backbone
depolymerization with the by-products being the respective alcohol and glyoxylic acid hydrate
(Figure 1.13), an intermediate in the glyoxylic acid cycle. 100, 101 Finally, the ester side group of
PEtG can be readily replaced with alcohols or amides. 102 Through the modification of the UV
light-responsive end-cap and addition of a bifunctional alkyne group, Gillies and coworkers were
able to use the linker end-cap to couple PEG, creating a stimuli-responsive, amphiphilic diblock
copolymer. The PEG portion of the diblock copolymer is not degradable but is instead released,
and is considered bioinert.48, 81 This diblock copolymer was capable of self-assembly in water
before UV exposure and subsequent degradation. Following this work, the Gillies group expanded
the polyglyoxylate family to include poly(butyl glyoxylate), poly(benzyl glyoxylate) and their
copolymers, which all demonstrated different properties.
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PEtG has been used to create particles for controlled drug release, by preparing blends of PEtG
and PLA loaded with the nonsteroidal anti-inflammatory drug celecoxib. 103 Multiple end-caps
were used, including the previously mentioned UV light-responsive end-cap and a disulfide capped
PEtG that responds to endogenous thiols. Partial degradation of the particles occurred when
exposed to stimulus, as expected due to PLA’s slow degradation time, but this work showed that
both PEtG could successfully be applied for drug delivery.
The Gillies group has also synthesized cleavable end-caps such as alkynyl trityl (AT), alkynyl
methoxy trityl (AMT), dimethoxy trityl (DMT) and monomethoxy trityl (MMT) that depolymerize
under physiological conditions (pH 5-7.4).104,

105

This degradation behavior was additionally

amplified with increasing temperature. The propargyl ether group associated with AMT and AT
was added such that an alkyne group is available for coupling with another block, allowing for
easy synthesis of diblock copolymers. (Figure 1.15)

Figure 1.15. Different stimuli-responsive end-caps that have been introduced onto the ends PEtG,
which cleave under physiological conditions (pH 5-7.4). The structure on the right features the
bifunctional alkyne group used to link the PEtG block to an additional polymer such as PEG.
PEtG degradation is influenced by temperature (Figure 1.16), and the time it takes for full
depolymerization of a sample can be decreased with increasing temperatures. As an example, at
22 °C, thin films of PEtG-DMT and PEtG-AMT lost ~ 50% of their mass over 5 days, while PEtGMMT and PEtG-AT took 15-20 days to lose 50% of their mass. When the temperature was
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increased to 30 °C (closer to physiological temperatures), PEtG-DMT and PEtG-AMT lost more
than 50% mass over the first day, with PEtG-MMT and PEtG-AT losing 50% of their mass over
3-5 days. The degradation rates of these end-caps are highly tunable, exemplified by the order-ofmagnitude decrease in degradation time associated with a single methoxy group addition. This
feature and the rapid depolymerization of uncapped PEtG under standard physiological conditions
should in theory allow for easily tunable, degradable drug delivery systems.

Figure 1.16 Temperature dependant degradation mechanism of trityl capped PEtG.

1.8

Thesis Hypothesis and Project Objectives

In vivo vascular micro-CT contrast media should provide suitable circulation times and contrast
enhancement in single-energy and dual-energy scan regimes. The use of materials such as iodine
is widespread, but new materials such as those based on lanthanides can provide higher contrast.
While recent research has shown the successful synthesis of lanthanide contrast media, 28 there is
still room for design optimization. As metal content and subsequent contrast increases, toxicity to
the animal must be mediated, while long circulation times need to be sustained. The underlying
hypothesis of this thesis is that by incorporating PEtG with end-caps designed to cleave and cause
depolymerization at controllable rates, we can fine-tune and facilitate the safe excretion of vascular
micro-CT lanthanide-based contrast agents, while maintaining suitable circulation times and high
metal loading. Two different approaches are proposed for exploring and testing this hypothesis.
Chapter 2 describes an approach where PEtG is functionalized with Gd-DTPA derivatives to create
a novel end-to-end degradable micro-CT contrast agent (Scheme 1.1). It is proposed that
functionalization of this polymer to incorporate many chelating molecules will allow for
circulation times suitable for vascular imaging and evading rapid clearance post injection.
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Following imaging, the PEtG backbone will degrade and release small Gd-DTPA molecules
capable of being cleared by the kidneys. DTPA will be used as a chelator and for proof-of-concept
purposes due to its ease of modification and low cost. If the concept shows promise, the chelator
can be changed in the future to better tune the properties of the contrast agent, such as their stability
with respect to transmetallation. This chapter will focus on the synthesis methods used to create
the poly(DTPA) molecules and the chelated poly(Gd-DTPA). Results for in vitro and in vivo
characterization by MTT assay and IV injections will also be presented.

Scheme 1.1. Polymeric chelate preparation and degradation scheme, resulting in small particles
for renal excretion.
Chapter 3 describes an attempt to further optimize the previous polymer encapsulated lanthanide
NP design (Scheme 1.2). A two-part solution is designed, where a degradable PEtG-PEG diblock
copolymer system will be used in tandem with 10 nm diameter NaGdF 4 NPs to create a novel
degradable polymer-nanoparticle contrast agent. The PEtG-PEG will serve to encapsulate the NPs,
resulting in colloidally stable assemblies with long circulation times, metal loading suitable for
micro-CT imaging, and low toxicity. The incorporation of the degradable block will potentially
aid in release of the encapsulated NPs, which will be synthesized with a 10 nm in diameter, small
enough for renal clearance. Two different end-caps, AT and AMT, will be studied due to their
cleavage being possible under physiological conditions (pH 5-7.4), in addition to having different
degradation times. The procedures for synthesizing the nanoparticles and diblock polymers,
followed by self-assembly to encapsulate the NPs will be described. Size, size distribution, and
26

metal content will be analyzed. Key findings of this work will be summarized and the implications
of these results for future work will be discussed.

Scheme 1.2. Contrast agent preparation, injection, and subsequent assembly breakdown from
polymer degradation.
Chapter 4 will summarize the conclusions from the thesis research and focus on the future
directions of the work, including the potential application of the materials to different imaging
modalities and new formulations for contrast media that benefit from this proof-of-concept work.
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Chapter 2
2
Development of Long-Circulating Degradable Poly(chelates)
for Pre-Clinical Microcomputed Tomography of the Vasculature
2.1

Introduction

Contrast agents for computed tomography (CT) can vary in terms of their high-density material,
which is often chosen depending on its k-edge, the energy at which a sudden spike of x-ray
attenuation occurs. Traditional CT contrast agents have iodine incorporated as an attenuating
material,1 which has a k-edge of 33.2 keV. Most micro-CT scanners can produce X-rays with
energies between 30-90 keV. While iodine provides adequate contrast, it has a low k-edge
compared to other explored materials, making the production of X-rays below the k-edge difficult
and limiting it’s use in more advanced techniques such as dual-energy micro-CT (DEMCT). New
high-density materials have been incorporated into contrast media to help provide more image
enhancement. An example is the gold nanoparticles found in Aurovist 15 nm, where the contrast
agent possesses almost 200 mg/mL of gold. Attenuation is increased with increasing concentration
(density in solution) and atomic number. As a result, gold can provide more contrast than iodine. 2
However, gold ultimately suffers from a similar limitation to iodine with respect to DEMCT, in
that it has a non-optimal k-edge, except that it has a high k-edge (80.7 keV), and it would be
difficult to sustain an excess of X-rays above this k-edge.
The lanthanides are a group of metals that possess special properties in medical imaging, most
notably in MRI and CT. Lanthanides such as erbium and gadolinium are very promising for use in
micro-CT imaging as they have k-edges that lie within the average energies of produced X-rays
(50-60 keV). This innate property allows for optimized performance in micro-CT and DEMCT. 3
In MRI, gadolinium is used for its paramagnetic properties, typically in the form of metal-chelates
which vary in shape and charge.1 Shape, referred to as macrocyclic or linear, involves “caging” or
“wrapping” around a metal, while charge is simply referred to as “ionic” or “non-ionic”. Either
shape can be ionic or non-ionic. Two common metal chelators that form the basis for many clinical
formulations are the linear diethylenetriaminepentaacetic acid (DTPA) and macrocyclic
2,2′,2′′,2′′′-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic

acid

(DOTA,

tetraxetan).4 A concern with gadolinium-based contrast agents is the possibility of metal ions
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leaching out of the chelate and undergoing transmetallation. 5, 6 When this happens, free Gd3+ ions
exchange with endogenous ions such as Ca2+ before binding to human tissue. Transmetallation is
associated with the limited stability of the chelate and extended exposure to the contrast agent.
Macrocyclic chelators such as DOTA generally have better stability with regards to
transmetallation, and are therefore regarded as more safe when being used with extended half-life
requirements, but they also require much longer to fully chelate the metal. 7
Aside from the k-edge material, contrast media are designed according to the desired clearance
route or administration pathway. While MRI contrast agents such as Gd-DTPA have bridged the
gap and been used in clinical CT-imaging,8 they still suffer from too short of circulation times for
vascular micro-CT and additionally require doses much larger than the manufacturers’
recommendations. The dosage difference between MRI and CT arises from the inherently linear
relationship between attenuation and the concentration of the contrast media in CT, whereas the
small dose associated with MRI is orders of magnitude less than that used in CT. Efforts to extend
circulation time include chemical modifications, such as the previously commercially available
vascular MRI contrast Ablavar. Ablavar’s phosphodiester linkage to a lipophilic albumin-binding
group afforded the molecule extended circulation times by reversibly binding to human serum
albumin.9 While this modification extended the circulation time of the chelate, it resulted in
comparitively higher risk of mild to moderate allergic reactions and was discontinued in 2017 due
to poor sales.10 The use of polymers – molecules with many repeat units – can also extend
circulation times of Gd3+ chelates by connecting multiple small molecules to a larger polymer
backbone. The increased hydrodynamic volume of a polymer compared to a small molecule results
in an extended half-life in the blood stream. With respect to this project, multiple chelate groups
connected together on a polymer backbone are referred to as poly(chelates). 11
Advances in polymer chemistry have allowed for the synthesis of a new category of polymers
known as self-immolative polymers (SIPs). These polymers are fitted with a variety of tunable
end-caps that respond to a single stimulus event, cleaving from the backbone leaving it to “unzip”
into its small-molecule constituents. Poly(ethyl glyoxylate) (PEtG), a type of SIP, benefits from
advantages such as a readily available monomer for its preparation and non-toxic degradation
products when compared to other SIPs.12-14 PEtG is higly tunable given the ability to change its
end-cap and resulting required stimulus. Our research group has previously synthesized PEtG with
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cleavable end-caps such as trityl (T) and monomethoxytrityl (MMT) that degrade under
physiological conditions (i.e., pH 7.4).15
The purpose of the current study was to create a long-circulating poly(chelate) contrast agent for
vascular micro-CT that can be excreted quickly, allowing for future imaging studies to be
performed without adverse effects on the animals. This chapter describes an approach to extending
the circulation time of gadolinium chelate-based contrast agents to that suitable for vascular microCT, while striving to achieve low toxicity. Multiple chelate groups are conjugated to a PEtG
backbone. After injection and imaging, a stimulus can trigger the end-cap to be cleaved from the
polymer terminus, resulting in depolymerization and the release of small molecule chelate
derivatives. We hypothesized that these small molecule chelates will not be bound to proteins and
will be excreted via the renal system. By encouraging rapid excretion, it was theorized that we
could reduce transmetallation and keep toxicity to a minimum. This targeted excretion concept has
been proven in imaging before, but in MRI and with a degradable polymer that required multiple
stimulus events.16 DTPA was selected to complex the Gd3+. Although DTPA is a linear chelator,
it is inexpensive and works well for proof-of-concept experiments. In terms of end-caps,
benzyloxymethyl (BOM) was used a stable control so the differences in excretion could be
monitored, and MMT/T capped polymers were used for the degradable samples as they are known
to be cleaved at the physiological pH of 7.4.15 The polymers were expected to degrade under
standard physiological conditions into small molecules capable of being cleared through the
kidneys, as opposed to hepatobiliary organs.17 The properties of a small library of poly(chelates)
were explored and tested in animals to evaluate toxicty and biodistribution. Their capabilities to
evade immediate excretion were monitored by time-course imaging over an hour, and
enhancement was tracked to determine efficacy.

2.2

Experimental

2.2.1 General Materials
Gadolinium chloride hexahydrate, N-methylethylenediamine, ethyl glyoxylate, and xylenol orange
were purchased from Alfa Aesar (USA). Sodium hydroxide, benzyloxymethyl chloride, (4-(4,6dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride) (DMTMM), and DTPA were
purchased from Thermo Fisher Scientific (USA). Deuterated chloroform, centrifugal dialysis tubes
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(15 mL, 50 kDa MWCO), deuterium oxide, silver triflate and trityl chloride were purchased from
Millipore Sigma (Oakville, ON). Spectra/Por 6 dialysis tubing (10 kDa MWCO) was obtained
from Spectrum Laboratories (Rancho Dominguez, CA). Normal saline (0.9 % NaCl) was
purchased from Cardinal Health (Mississauga, ON). Mouse Primary Antibody Isotype Control,
which is a mouse serum mimic, fetal bovine serum (FBS), Glutamax (100x) solution Penstrep
(100x), and Dulbecco’s modified Eagle’s medium were obtained from Invitrogen Corporation
(Camarillo, CA). C57BL/6 male mice (25–30 g) were purchased S3 from Jackson Laboratories
(Bar Harbor, ME), isoflurane from Baxter Corporation (Mississauga, ON) and diphenhydramine
from Sandoz (Boucherville, QC). Deionized water was collected using a MilliQ water purification
system purchased from Millipore Sigma (Oakville, ON). With exception of ethyl glyoxylate,
which was purified as previously reported,18 all chemicals were used as purchased, without further
purification. Inductively coupled plasma mass spectrometry (ICP-ms) analysis was conducted by
the Biotron Experimental Climate Change Research Centre (London, Canada) according to the US
EPA Method 200.8.

2.2.2 General Methods
Hydrodynamic diameters were measured by dynamic light scattering (DLS) using a Zetasizer
Nano S instrument (Malvern Instruments Ltd, Malvern UK) at room temperature (37 °C) in a
quartz cuvette (1 mg/mL). Fourier transform-infrared (FT-IR) spectra were recorded using a
PerkinElmer Spectrum Two FT-IR spectrometer with an attenuated total reflectance (ATR)
attachment and a single reflection diamond. Centrifugal dialysis was performed using a VWR
Clinical 200 centrifuge with a 28° fixed rotor angle. 1H and 13C nuclear magnetic resonance (NMR)
spectra were obtained using either a 400 MHz Bruker AvIII instrument or a 600 MHz Varian
INOVA 600 instrument (Milton, ON). 1H NMR chemical shifts were calibrated against the residual
solvent signal of CDCl3 (7.26 ppm) for PEtG and D2O (4.79 ppm) for all other polymers. 13C {1H}
NMR chemical shifts were calibrated against the residual solvent signal of CDCl 3 (77.16 ppm),
dioxane (67.19 ppm) and diethyl ether (66.42 ppm). Size exclusion chromatography (SEC) was
performed using an a Viscotek GPC Max VE2001 solvent module equipped with a Viscotek
VE3580 RI detector operating at 30°C, and a Malvern 270 Dual detector. The separation technique
employed two Agilent Polypore (300 × 7.5mm) columns connected in series and to a Polypore
guard column (50 × 7.5mm). Samples were dissolved in tetrahydrofuran (THF) (glass distilled
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grade) at approximately 5 mg/mL concentrations, filtered through 0.22 µm syringe filters and
injected using a 100 µL loop. The THF eluent was filtered and eluted at 1 mL/min for a total of 30
minutes. A calibration curve was obtained from poly(methyl methacrylate) (PMMA) standards
with molecular weight ranges of 690 – 790,000 g/mol.

2.2.3 Synthesis of Poly(ethyl glyoxylates)
Synthesis of L-PEtG-T: Toluene was distilled over sodium and benzophenone under nitrogen at
atmospheric pressure before use. To 60 mL of dried toluene in a Schlenk flask under N 2, n-butyl
lithium solution was added (0.43 mL, 0.60 mmol, 1.0 equiv.). Purified ethyl glyoxylate (15 mL,
150 mmol, 250 equiv.) was subsequently added and the entire polymerization mixture was cooled
to −20 ºC. In a separate flask, trityl chloride or (1.7 g, 6.0 mmol, 10 equiv.) and silver triflate (0.52
g, 2.0 mmol, 3.3 equiv.) were placed and the flask was evacuated and purged with N 2. A 5.0 mL
aliquot of dried toluene was added, and the flask contents were mixed at 70 ºC for 1 h to yield the
end-cap mixture. After 30 min, dried NEt3 (1.67 mL, 12.0 mmol, 20.0 equiv.) was added to the
polymerization flask. After 1 h, the contents of the end-cap mixture flask were cooled to −20 ºC
before 20 mL of dry CH2Cl2 were added and the mixture was pipetted into the polymerization
flask. The polymerization flask was then capped and closed off from the N 2 line before being
allowed to warm to room temperature overnight. Purification was achieved by concentrating the
polymerization mixture and precipitating it in 660 mL of a 10:1 MeOH:water mixture. After
decanting, the purified residue was dissolved in CH 2Cl2, mixed with activated charcoal, and
filtered through Celite before being concentrated to afford 5.1 g of an orange tacky solid. Yield =
33%. 1H NMR (CDCl3, 400 MHz): δ 7.45 (s, 6H), 5.41-5.76 (m, 243H), 4.21 (s, 486H), 1.28 (s,
730H), 0.87 (s, 3H). 13C {1H} NMR (CDCl3, 100 MHz): δ 165.4, 126.0-129.7, 90.26-94.1, 61.9,
13.7. FT-IR: 2985, 1748cm-1. SEC (THF, PMMA): Mn = 24.9 kg/mol, Mw = 33.0 kg/mol, Đ = 1.3.
L-PEtG-MMT: PEtG-MMT was synthesized using a similar procedure to PEtG-T, except that 4monomethoxytrityl chloride was added as the end-cap precursor. Yield = 80%

1

H NMR (CDCl3,

400 MHz): δ 7.46 (s, 6H), 5.39 – 5.78 (m, 255H), 4.20 (s, 510H), 1.29 (s, 765H), 0.88 (s, 3H) .
13

C {1H} NMR (CDCl3, 100 MHz): δ 166.0, 91.1–94.6, 62.5, 14.3. FT-IR: 2985, 1749 cm-1. SEC

(THF, PMMA): Mn = 25.6 kg/mol, Mw = 38.1 kg/mol, Đ = 1.49.

40

L-PEtG-BOM: PEtG-BOM was synthesized using a similar procedure to PEtG-T, except that
NEt3 and the end-cap precursor (benzyloxymethyl chloride) were added at 40 and 20 equivalents
respectively for end-capping. Silver triflate was not used for this reaction. After purification, a
clear, tacky solid was obtained. Yield = 77%. 1H NMR (CDCl3, 400 MHz): δ 5.44-5.79 (m, 1H),
4.21 (s, 2H), 1.28 (s, 3H). 13C {1H} NMR (CDCl3, 100 MHz): δ 165.7, 127.2-129.8, 90.26-94.6,
62.2, 14.0. FT-IR: 2985, 1748 cm-1. SEC (THF, PMMA): Mn = 29.3 kg/mol, Mw = 39.3 kg/mol, Đ
= 1.34
H-PEtG-T. Purified ethyl glyoxylate (6.0 mL, 61 mmol, 1.0 equiv) was dissolved in 20 mL of dry
CH2Cl2, followed by a drop (~50 μL) of dry NEt3. The mixture was cooled to −20 °C and stirred
for 1 h. Additional dry NEt3 (0.13 mL, 0.93 mmol, 0.015 equiv) was added to the mixture, followed
by AgOTf (0.23 g, 0.90 mmol, 0.015 equiv) and trityl chloride (0.26 g, 0.90 mmol, 0.015 equiv).
The mixture was allowed to rise to room temperature overnight before being concentrated and
precipitated in 20:200 mL water:MeOH to afford 3.4 g of a clear, colourless, tacky solid. Yield =
55%. 1H NMR (CDCl3, 400 MHz): δ 7.45 (s, 12H), 5.46-5.76 (m, 487H), 4.21 (s, 984H), 1.28 (s,
1471H). 13C {1H} NMR (CDCl3, 100 MHz): δ 166.0, 90.5-94.9, 62.5, 14.3. FT-IR: 2985, 1748 cm1

. SEC (THF, PMMA): Mn = 48.7 kg/mol, Mw = 74.4 kg/mol, Đ = 1.53

H-PEtG-MMT. H-PEtG-MMT was synthesized using the same procedure as H-PEtG-T except
4-monomethoxytrityl chloride (0.28 g, 0.91 mmol, 0.015 equiv) was used to afford 3.5 g of a clear,
pale-orange, tacky solid. Yield = 57%.1H NMR (CDCl3, 400 MHz): δ 7.45 (s, 12H), 5.45-5.84 (m,
431H), 4.22 (s, 853H), 1.29 (s, 1271H). 13C {1H} NMR (CDCl3, 100 MHz): δ 165.7, 90.7-94.1,
62.2, 14.0. FT-IR: 2985, 1748 cm-1. SEC (THF, PMMA): Mn = 44.8 kg/mol, Mw = 79.6 kg/mol, Đ
= 1.77

2.2.4 Synthesis of Polyglyoxylamides
L-PEtG-T (0.95 g, 9.5 mmol ester, 1.0 equiv.) and N-methylethylenediamine (2.1 g, 29 mmol, 3.0
equiv.) were added to dioxane (50 mg/mL PEtG) and the reaction mixture was stirred at room
temperature for 16 h. The solution was then precipitated into diethyl ether twice (50 mL/300 mg
product), dissolving in a minimum amount of dichloromethane between precipitations. The
polymer was then redissolved and moved from the large precipitation flask to a collection vial
before excess solvent is removed via rotovap. The resulting product (915 mg) was isolated as a
white, glassy solid. Yield = 70%. 1H NMR (D2O, 400 MHz): δ 5.61 (br s, 1H), 3.36 (s, 2H), 2.71
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(s, 2H), 2.34 (s, 3H). 13C {1H} NMR (D2O, 100 MHz): δ 167.2, 128.5, 92.4-98.1, 48.8, 38.2, 34.3.
FT-IR: 3286, 3075, 2935, 2846, 2798, 1663, 1539 cm -1.
L-PGAm-MMT: This polymer was prepared by the same procedure described above for LPGAm-T, except that L-PEtG-MMT was used as the starting material. Yield = 76%. 1H NMR
(D2O, 400 MHz): δ 5.60 (bs, 1H), 3.36 (s, 2H), 2.72 (s, 2H), 2.34 (s, 3H).

13

C {1H} (D2O, 100

MHz): δ 167.1, 92.0-98.2, 48.9, 38.3, 34.4. FT-IR: 3287, 3070, 2935, 2850, 2798, 1664, 1539 cm 1

.

L-PGAm-BOM: This polymer was prepared by the same procedure described above for LPGAm-T, except that L-PEtG-BOM was used as the starting material. Yield = 63 % 1H NMR
(D2O, 600 MHz): δ 5.60 (br s, 1H), 3.37 (s, 2H), 2.71 (s, 2H), 2.34 (s, 3H). 13C {1H} NMR (D2O,
100 MHz): δ 167.7, 94.3-98.5, 49.5, 39.1, 35.1. FT-IR: 3291, 3074, 2937, 2850, 2799, 1663,1539
cm-1.
H-PGAm-T: This polymer was prepared by the same procedure described above for L-PGAm-T,
except that H-PEtG-T was used as the starting material. Yield = 40 % 1H NMR (D2O, 400 MHz):
δ 5.60 (br s, 1H), 3.36 (s, 2H), 2.70 (s, 2H), 2.33 (s, 3H). 13C {1H} NMR (D2O, 100 MHz): δ 167.7,
93.5-98.5, 49.5, 39.1, 35.1. FT-IR: 3290, 3076, 2937, 2850, 2799, 1662,1539 cm -1.
H-PGAm-MMT: This polymer was prepared by the same procedure described above for PGAmT, except that H-PEtG-MMT was used as the starting material. Yield =57 % 1H NMR (D2O, 400
MHz): δ 5.60 (br s, 1H), 3.35 (s, 2H), 2.72 (s, 2H), 2.34 (s, 3H). 13C {1H} NMR (D2O, 100 MHz):
δ 167.5, 94.0-97.4, 49.4, 39.2, 34.9. FT-IR: 3288, 3077, 2939, 2849, 2799, 1661,1539 cm -1.

2.2.5 Synthesis of DTPA-functionalized PGAms
L-PGAm-DTPA-T: DTPA (6.1 g, 15 mmol, 20 equiv.) was added to 10 mL of MilliQ water and
the pH was adjusted to 8.5 with 4 M NaOH. 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) (1.7 g, 6.2 mmol, 8.0 equiv.) was dissolved in 15 mL of
deionized water, added to the DTPA solution, and the mixture was stirred for 5 min. L-PGAm-T
(100 mg, 0.8 mmol, 1 equiv.) was dissolved in 18 mL of deionized water, added to the
DMTMM/DTPA solution, and the resulting solution was stirred for 1 h. The product was purified
using centrifugal dialysis against deionized water (6×15 mL 50 kDa tubes, 6000 rpm, 15 min, 9
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washes). The final solution was lyophilized, leaving 265 mg of white, fluffy powder. Yield = 58%.
1

H NMR (D2O, 600 MHz): δ 5.56 (br s, 1H), 2.64–4.42 (m, 25H). 13C{1H} NMR (D2O, 100 MHz):

δ 176.4, 172.2, 167.3, 94.2, 57.3, 51.9, 49.8, 47.1, 35.3. FT-IR (ATR): 3270, 2950, 2840, 2360,
1630 cm−1.
L-PGAm-DTPA-MMT: This polymer was prepared by the same procedure described above for
L-PGAm-DTPA-T, except that L-PGAm-MMT was used as the starting material. From L-PGAmMMT (300 mg, 2.3 mmol, 1.0 equiv.) and DTPA (18.1 g, 46.1 mmol, 20 equiv.), 471 mg of white,
fluffy powder was afforded. Yield = 36%.1H NMR (D2O, 600 MHz): δ 5.63 (s, 1H), 2.64-4.42
(m,32H). FT-IR: 2951, 2828, 2358, 1627, 1595, 1398 cm -1.
L-PGAm-DTPA-BOM: This polymer was prepared by the same procedure described above for
L-PGAm-DTPA-T, except that L-PGAm-BOM was used as the starting material. From L-PGAmBOM (265 mg, 2.0 mmol monomer, 1.0 equiv.) and DTPA (16.0 g, 40.7 mmol, 20 equiv.), 549
mg of white, fluffy powder was afforded. Due to BOMs stability, the material was purified by
dialysis against deionized water over 2 days (5 dialysate changes). Yield = 48%. 1H NMR (D2O,
400 MHz): δ 5.57 (br s, 1H), 2.64-4.42 (m, 32H).

13

C {1H} (D2O, 150 MHz): δ 176.4, 172.2,

167.3, 94.22, 57.3, 51.9, 49.8, 47.1, 35.3. FT-IR: 3280, 2951, 2850, 2365, 1615, 1399 cm -1.
H-PGAm-DTPA-T: This polymer was prepared by the same procedure described above for LPGAm-DTPA-T, except that H-PGAm-T was used as the starting material. From H-PGAm-T (300
mg, 2.3 mmol, 1.0 equiv.) and DTPA (18.1 g, 46.1 mmol, 20 equiv.), 809 mg of white, fluffy
powder was afforded. Yield = 62%. 1H NMR (D2O, 600 MHz): δ 5.53 (br s, 1H), 2.63-4.42 (m,
27H). 13C {1H} (D2O, 100 MHz): δ 175.6, 173.5, 167.3, 94.5, 57.5, 51.4, 50.3, 46.9, 35.4. FT-IR:
3265, 2945, 2835, 2356, 1593, 1398 cm-1.
H-PGAm-DTPA-MMT: This polymer was prepared by the same procedure described above for
L-PGAm-DTPA-T, except that H-PGAm-MMT was used as the starting material. From H-PGAmMMT (265 mg, 2.0 mmol monomer, 1.0 equiv.) and DTPA (16 g, 40.7 mmol, 20 equiv.), 549 mg
of white, fluffy powder was afforded. Yield = 34%. 1H NMR (D2O, 600 MHz): δ 5.52 (br s, 1H),
2.65-4.43 (m, 27H). FT-IR: 3269, 2951, 2850, 2357, 1621, 1396 cm -1.

43

2.2.6 Degradation of PGAm-DTPAs
L-PGAm-DTPA-T, L-PGAm-DTPA-MMT, L-PGAm-DTPA-BOM, H-PGAm-DTPA-T and HPGAm-DTPA-MMT were each dissolved in 1.0 mL of deuterated phosphate buffered saline
solution. All solutions were prepared at a concentration of 10 mg/mL, sealed, and stored at 37 °C.
1

H NMR spectra were obtained at 37 °C using a delay time of 30 s and 64 scans. Degradation was

monitored by acquiring multiple 1H NMR spectra at specific time points and comparing the
integration ratios of the polymerized backbone methine proton at ~5.6 ppm and the methine proton
of the degradation product at ~5.3–5.5 ppm.

2.2.7 Chelation of Gd3+ into PGAm-DTPAs
PGAm-DTPA (25.0 mg, 0.04 mmol DTPA, 1.0 equiv.) was dissolved in 3 mL of deionized water,
with the pH adjusted to 7 using 0.1 M NaOH. GdCl 3 ● 6H2O (15.0 mg, 0.04 mmol, 1 equiv.) was
dissolved in 1 mL of deionized water and added slowly (15 min), to the polymer solution. During
additions, the solution was monitored, and the pH adjusted to stay at 7 with 0.1 M NaOH.
Following chelation, the solution was stirred for 5 min before filtering and subsequent centrifugal
dialysis using deionized water (3 × 15 mL tubes, 3 washes, 6000 rpm, 30 mins).
UV-Vis Spectroscopy for Free Gd3+ Analysis. UV-visible spectra were obtained on a Varian
UV/VIS Cary 300 spectrophotometer. Following the method of Barge et al,20 free gadolinium
concentrations can be calculated by the ratio of two absorbances when chelating the metal into a
solution of xylenol orange and acetate buffer.

𝐺𝑑

∝

(2.1)

Through the construction of a standard curve, the amount of free gadolinium in a solution can be
calculated using measured absorbance values.

𝐺𝑑

=𝐴+𝐵

(2.2)

A 300 µL aliquot of post-chelation dialysate from each run was added to 3 mL of the xylenol
orange/acetate buffer solution and absorption values were measured to quantitatively assess excess
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gadolinium. Proper preparation of the buffer/indicator solution also allowed for rough qualitative
assessment of free gadolinium through the color shift of the xylenol orange (Figure 2.1).

Figure 2.1. Qualitative assessment of varying molarities of gadolinium when added to the xylenol
orange/acetate buffer solution.
After 3 centrifugal dialysis washes each polymer solution contained less than 10 µM of Gd 3+, so
the dialyzed solution was lyophilized, leaving a white powder, yield = 65%.

2.2.8 In vitro Toxicity Evaluation of the Contrast Agent
L-PGAm-DTPA-Gd-T,

L-PGAm-DTPA-Gd-MMT,

L-PGAm-DTPA-Gd-BOM,

H-PGAm-

DTPA-Gd-T and H-PGAm-DTPA-Gd-MMT were tested. C2C12 mouse myoblast cells were
seeded in a Nunclon 96-well U-bottom transparent polystyrol plate to obtain approximately 10,000
cells/well in 100 μL of Dulbecco’s modified Eagle’s medium containing serum, glutamax, and
antibiotics. The cells were allowed to adhere to the plate in a 5% CO 2 incubator at 37 °C for 24 h.
The growth medium was then aspirated and replaced with either solutions of sodium dodecyl
sulfate (SDS) in the cell culture medium at concentrations of 0.2, 0.15, 0.10, or 0.05 mg/mL, which
were used as positive controls, serial dilutions of the contrast agents, or fresh medium. The cells
were then incubated at 37°C (5% CO2) for 24 h. The medium was again aspirated and replaced
with 110 μL of fresh medium containing 0.5 mg/mL (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) (MTT). After 4 h of incubation (37°C, 5% CO 2), the MTT solution
was carefully aspirated and the purple crystals were dissolved by addition of 50 μL of
spectroscopic grade dimethyl sulfoxide (DMSO). After shaking (1 s, 2 mm amp, 654 rpm), the
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absorbance of the wells at 540 nm was read using an M1000-Pro plate reader (Tecan). The
absorbance of wells prepared in the same way but without cells was subtracted as a background
and the cell viability was calculated relative to wells containing cells that were exposed only to the
culture medium. Cell viability was detected for cells exposed to only the lowest concentrations of
SDS, confirming the sensitivity of the assay. Eight replicate samples per concentration were
prepared and measured to ensure accuracy and reproducibility.

2.2.9 General Micro-CT Imaging and Analysis Methods
Micro-CT images were acquired with the GE Locus Ultra (London, Canada) with a protocol
previously used for evaluation of contrast media in vivo.21, 22 Images were acquired with 1000
views (16 ms per view) at 80 kVp, 55mA over 360° and reconstructed using a cone-beam
reconstruction algorithm. Phantom images were aquired with a similar protocol but utilized 120
kvP and 80 mA to account for beam-hardening from the acrylic phantom. This difference in
energies does not affect the animal images or any information obtained from them, as the higher
energy scan is only used to construct an accurate standard curve to determine the injected aliquots
concentration. This concentration does not change and the HU measurements do not correlate
between phantom and mouse images. The final images have a voxel size of 150 x 150 x 150 μm.
Images were examined using Microview (Parallax Innovations, Canada) and CT contrast was
measured in Hounsfield Units (HU is a dimensionless, standard, linear scale of X-ray attenuation
coefficient measured in CT, where water = 0 HU and air = −1000 HU). All HU values were
obtained by averaging the values within a reagion of interst that was 450 × 450 × 150 μm.

2.2.10

Micro-CT Imaging of Concentrated Contrast Media

The relationship between gadolinium concentration and HU was determined through the
construction of a standard curve. Gadolinium chloride was diluted in saline at concentrations of 5,
10, 25, 50 and 100 mg/mL and HU values were determined. The linear regression between metal
concentration and CT number was then used to determine gadolinium concentrations in each of
the highly concentrated samples. All injected dosages were scanned in an acrylic phantom with
prepared gadolinium standards so that an accurate, quantifiable concentration of metal and
polymer was known before administration.
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2.2.11
Intravenous Administration of the Contrast Media and In Vivo
Distribution
Preliminary in vivo studies used two C57BL/6 male mice (25-30 g), and final in vivo studies used
six C57BL/6 male mice (25-30 g). Mice were anesthetized initially with 4% isoflurane, followed
by 1.5% for maintenance, in O2 through the placement on nose cones on the snouts of the animals.
When anesthetized for extended periods of time, mice were kept warm with infrared lamps,
previously shown to help maintain body temperature near 37 °C. 21 The mice were each imaged
and then the tail veins were catheterized using PE-20 polyethylene tubing for subsequent contrast
agent administration. Approximately 0.2 mL of a contrast agent, with concentrations ranging 49 –
70 mg Gd/mL was injected over a period of 5 min, following which imaging occurred at 5 min
intervals for the first hour, and then at 4 h, 24 h and 1 week. The contrast agent dosage was prepared
via gradual addition of the dried poly(chelate) material to sterile saline until a concentration limit
had been reached. This concentration limit was determined by qualitatively observing if a small
stir bar could successfully continue to spin, and the stoppage of the stir bar corresponded to a
concentration that could only be passed through the catheter after being heated to near
physiological temperature (37 °C). Animals were administered 0.2 mL after injection of the
contrast agent to flush the catheter, and received an additional 0.2 mL of saline subcutaneously to
assist in recovery. All animal studies were carried out in accordance with the regulations set out
by the University of Western Ontario’s Council on Animal Care, in agreement with the ARRIVE
guidelines (AUP#2018-001, Appendix 3) and were carried out in accordance with the U.K.
Animals Act, 1986 and associated guidelines.

2.2.12

Histological Analysis of Excised Tissues

Clearance organs (liver, spleen and kidneys) were excised from the mice following euthanasia at
28 days post-injection. Histological images of a single mouse from each formulation group were
acquired and compared to a histological images of a healthy control mouse. Haematoxylin was
used to stain the nuclei of cells purple, while eosin counterstained the extracellular matrix and
cytosol pink.23
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2.2.13

Statistical analysis

All values are reported as means ± standard deviations. A two-way repeated-measures analysis of
variance (ANOVA) was performed in Prism 8 (GraphPad Software Inc., San Diego, CA, USA)
for each formulation to evaluate differences between the contrast enhancement in the vasculature
and body weight changes. Results were considered statistically significant at p < 0.05.

2.3

Results and Discussion

2.3.1 Polymer synthesis
Five different end-capped poly(ethyl glyoxylate)s (PEtG) were used as starting polymers for this
work (Scheme 2.1). The three different end-caps including trityl (T), monomethoxytrityl (MMT),
and benzyloxymethyl (BOM) (Scheme 2.1) were selected for their varying degradation times,
where BOM is considered a stable control and MMT/T are degradable end-caps designed to cleave
in the pH range of 5.0–7.4. Both low (L) and high (H) molar mass versions of the T and MMT
polymers were prepared as the polymer length was anticipated to influence the blood circulation
time. The low molar mass PEtGs were synthesized as previously reported by initiation using nbutyl lithium,24 leading to Mn values of 25 – 29 kg/mol based on SEC (Figure A1.35). As the nbutyl lithium initiation method is much less effective for obtaining high molar mass polymers, 18
these were prepared using our earlier PEtG synthesis method involving initiation from residual
monomer hydrate with triethylamine as a proton transfer catalyst. 25 SEC indicated Mn values of 45
– 49 kg/mol. It was not possible to prepare a high molar mass version of the BOM capped polymer
due to the poor reactivity of this endcap under the polymerization conditions.
Table 2.1. SEC data for the PEtGs.

Polymer

Mn (kg/mol)

Mw (kg/mol)

Đ

L-PEtG-T

25

33

1.3

L-PEtG-MMT

26

38

1.5

L-PEtG-BOM

29

39

1.3

48

H-PEtG-T

49

74

1.5

H-PEtG-MMT

45

80

1.7

49

Scheme 2.1. Synthesis route of PGAm-DTPA, including the various end-cap molecules that were
used.
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The reaction to convert the PEtGs to PGAms (Scheme 2.1) was performed by adding N-methyl1,3-propanediamine to solutions of the PEtGs in dioxane at room temperature for 16 h. After
purification by precipitation, qualitatively, the tacky PEtGs changed to brittle, glassy materials
upon their conversion to PGAms. 1H NMR spectroscopy confirmed the conversion of PEtG to
PGAm by the disappearance of peaks at 4.2 and 1.3 ppm corresponding to the ethyl ester CH 2 and
CH3 groups (Figure 2.2a). In addition, new peaks corresponding to the pendant methylaminoethyl
amide groups appeared at 3.4, 2.7, and 2.3 ppm (Figure 2.2b). Due to the change in solubility upon
conversion from PEtG to PGAm, the NMR spectra of the PGAms were taken in D2O, preventing
a signal from the newly formed secondary amide from appearing on the 1H NMR spectra. The
amidations were also confirmed by FT-IR spectroscopy based on the characteristic C═O amide
stretch of the PGAm at ∼1650 cm−1, in contrast with PEtG, which has a characteristic C═O ester
stretch at ∼1750 cm−1 (Figures A1.30-A1.34). Due to the presence of the pendant secondary
amines, which led to column adsorption, SEC data could not be obtained. However, we have
previously established that the amidation conditions do not lead to any significant backbone
degradation.24
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Figure 2.2. Stacked 1H NMR spectra of synthesized polymers: L-PEtG-T (CDCl 3, 400 MHz),
DTPA, L-PGAm-T, L-PGAm-DTPA-T (D2O, 600 MHz). The blue stars indicate solvents such as
dioxane, D2O and CDCl3.

The functionalization of the PGAms with DTPA pendant groups involved the conjugation of the
carboxylic acid of DTPA with the PGAm’s pendant secondary amines using DMTMM as a
coupling agent in water at pH 8.5 (Scheme 2.1). The challenge with this functionalization was the
5 carboxylic acid groups present on DTPA. To avoid the possibility of a single DTPA molecule
reacting with multiple amine groups, and leading to cross-linking, a very large excess (80 equiv.)
is typically added,26 but this can amount to over 20 g of DTPA being used for only 100 mg of
PGAm. As a result, the initial coupling reactions were conducted with 20, 40 and 80 equivalents
of DTPA to assess any differences in functionalization or cross-linking. If a reduction in
equivalents were to induce cross-linking, DLS diameter distributions would show larger species
52

than the expected diameters of ~10 nm. Ultimately, we found a negligible difference when altering
DTPA equivalents, and therefore selected 20 equivalents for the remainder of the work (Figure
A1.29).
The resulting DTPA-functionalized polymers PGAm-DTPA-T, PGAm-DTPA-MMT, and PGAmDTPA-BOM were characterized by 1H NMR, 13C NMR, and FT-IR spectroscopic methods. High
quality 1H NMR spectra proved difficult to obtain due to the bulky structure of the DTPA
functional groups, which led to long relaxation times for the polymer backbone. As such, a
relaxation delay of 30 s was used. DTPA has a total of 16 protons that should be observed in D 2O
as the COOH and NH protons exchange with deuterium and are therefore not observed (Figure
2.2c). These peaks can shift in location depending on the pH of the solution, but typically still fall
in the range of 2.8 – 4.0 ppm (Figure 2.2d).27 These protons also overlap with the two CH2 pendant
groups of the PGAm, as well as the CH 3 of the pendant amino group of the PGAm, which shifted
downfield from 2.3 ppm upon conjugation of DTPA. However, evidence of successful DTPA
conjugation came from the appearance of a new peak at ~4.1 ppm corresponding to the CH 2
adjacent to the newly formed amide. Based on the disappearance of the methylamino peak at 2.3
ppm and the integration of the DTPA peaks relative to the PGAm backbone peaks, the coupling
of DTPA occurred quantitatively (Figures A1.11-A1.15). FT-IR spectroscopy (Figure A1.30)
further confirmed functionalization of the PGAm backbone with DTPA. First, the unfunctionalized
PGAm had a secondary amine with N–H bending peaks at 1540 cm −1. Upon conversion to tertiary
amides in the PGAm-DTPA, these peaks broadened and shifted to overlap with the intense peak
at ~1630 cm-1 In addition, the broadening of the peak at ~3300 cm -1 is likely due to the presence
of carboxylic acids on the PGAm-DTPA. 13C NMR spectra were difficult to obtain due to the long
relaxation delay requirement, combined with the designed degradability of PGAm-DTPA-T and
PGAm-DTPA-MMT. However, the downfield shift of the peak corresponding to the CH 2 group
adjacent to the pendant secondary amines on the PGAm (~39 ppm) served as an indicator that the
amines were converted to amides during synthesis (Figure A1.21, A1.26).

2.3.2 Depolymerization of PGAm-DTPAs
Depolymerization of L-PGAm-DTPA-T, L-PGAm-DTPA-MMT, L-PGAm-DTPA-BOM, HPGAm-DTPA-T and H-PGAm-DTPA-MMT in deuterated PBS at 37 °C were measured using 1H
NMR spectroscopy (Figure 2.3A, A1.36-1.39). The backbone methine proton signal at ~6 ppm
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gradually decreased in intensity as the polymers degraded. The degradation products, mainly
functionalized monomer hydrates, gave rise to a methine proton signal at ~5.4 ppm. The presence
of two peaks associated with the monomer hydrate is hypothesized to be a result of rotational
isomers about the amide bonds. L-PGAm-DTPA-T underwent a gradual degradation over the
course of 1 month. In contrast, L-PGAm-DTPA-MMT degraded much more rapidly, reaching
100% degradation in only 8 hr. L-PGAm-DTPA-BOM showed little to no degradation beyond the
uncapped polymer chains present in solution. Interestingly, H-PGAm-DTPA-T and H-PGAmDTPA-MMT exhibited degradation times that were approximately half those of their lower molar
mass counterparts, with about 14 days and 4 hr. respectively required for complete
depolymerization. It can be theorized that in this instance, where x = number of end-caps, that the
stoichiometric equivalent of 1 additional end-cap (x+1), causes a reciprocal equivalent decrease in
the time required for full degradation (1/n × degradation time). This theory is explained by the
knowledge that SIP and PEtG-derivative depolymerization requires a single end-cap cleavage to
fully depolymerize, and this instance provides a second, additional point at which the
depolymerization could begin.
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Figure 2.3. (A) NMR spectra showing the depolymerization of H-PGAm-DTPA-T in deuterated
phosphate buffered saline (PBS) (1X, D2O) at 37 °C using a relaxation delay time of 30 seconds,
64 scans (D2O/PBS, 600 MHz). Over time there was an increase in signal from the methine proton
peak of the functionalized monomer hydrate at ~5.3–5.5 ppm, and a decrease in signal from the
backbone methine proton peak at ~5.7 ppm. (B) Depolymerization data for all of the PGAmDTPAs were obtained under the same conditions.
While PEtG is highly hydrophobic, its conversion to a PGAm with pendant amines and subsequent
functionalization with DTPA yields a polar molecule. PGAms degrade substantially faster when
compared to their PEtG counterparts, likely due to a proposed hydrogen bonding mechanism
where the oxygen adjacent to the end-cap forms a 5-membered ring with the amide of the last
repeat unit.24, 25 This intermediate assists end-cap cleavage, and the resulting uncapped polymer
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can then undergo depolymerization. Whereas previous experiments have examined the
degradation of PGAms in acidified organic solvent (and some in water), 24 this work showed a
similar, rapid depolymerization behavior, but focused on water as a solvent. Water plays a key role
in trapping the trityl cation post-cleavage, such that it cannot re-attach to the backbone and
depolymerization proceeds. Additionally, previous depolymerization studies were conducted at
room temperature,24 and we hypothesize that the elevated temperatures in these experiments
contribute to the accelerated degradation rates. The BOM-capped polymers lack of degradation
was as expected, as the end-cap is stable and was not expected to be cleaved under the experimental
conditions. As for the MMT/T samples, the rapid increase in degradation rate with the MMTcapped polymer is due to the added resonance stabilization of the resulting carbocation generated
upon cleavage that the methoxy group provides. This additional stability means a more readily
cleavable leaving group (end-cap), drastically accelerating end-cap cleavage rates and ultimately
backbone depolymerization. The increase in degradation rate associated with the higher molar
mass polymers can be attributed to their two cleavable end-caps, either one of which can enable
depolymerization to initiate when cleaved off.
Overall, these depolymerization studies confirmed that we had created a small library of
functionalized PGAms with tunable degradation rates. The trityl-capped polymers ultimately
degrade too slowly for the objective of this work, aimed at clearing the contrast agent rapidly after
the requisite imaging period. However, the MMT-capped polymers were of significant interest, as
they should be excreted by the kidneys after breaking down into small molecules.

2.3.3 Preparation and characterization of PGAm-DTPA-Gd
Gd3+ was chelated by the PGAm-DTPA polymers by dropwise addition of a GdCl 3 solution into a
stirring solution of the polymer. The solution was monitored closely to ensure that the pH stayed
at ~7.4. Chelation of DTPA with Gd3+ will lead to acidification of the solution as protons from the
DTPA are released into solution upon binding, which could lead to premature cleavage of the endcaps due to their sensitivity to acid. Once all of the gadolinium solution was added, additional
sodium hydroxide was added to the solution to remove any unchelated Gd 3+ as insoluble
precipitates in the form of Gd(OH)3 via filtration, and to react with HCl produced in-situ. The
subsequent removal of any remaining Gd3+ by dialysis was confirmed by assessment of Gd3+ in
the dialysate using the xylenol orange assay.20 FT-IR spectroscopy (Figure A1.30) confirmed
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metal chelation had occurred as the peak corresponding to the C=O stretch shifted from ~1625
cm−1 to ~1600 cm−1.28 The reduction in intensity of the peak at ~1400 cm−1 is due to the loss of the
O–H bend from the carboxylic acid groups. NMR spectroscopy could not be used due to the
inherent paramagnetic properties that Gd possesses.
ICP-MS was used to confirm the efficient chelation of Gd 3+ by the polymers. If every repeat unit
of the polymer had been functionalized with DTPA and subsequently chelated Gd 3+, the metal
content would be 24% (w/w). The values obtained for the low molar mass polymers were all
slightly higher than this theoretical value (Table 2.2). These results can likely be attributed to the
small amounts of residual Gd-DTPA, which has a theoretical Gd 3+ content of 29% (w/w), as DTPA
was used in large excess to functionalize the polymers. On the other hand, the high molar mass
polymers had a somewhat lower Gd3+ content of 20%. Solutions of these polymers had noticeably
higher viscosity than those of the shorter polymers which may have contributed to a lower
functionalization efficiency when linking the DTPA to the backbone or chelating the metal,
ultimately decreasing total metal loading. Due to the broadness of the peaks in the NMR spectra
of the PGAm-DTPA polymers, this slightly lower degree of functionalization may have been
difficult to detect.

Table 2.2: Metal content, in vitro characterization and 1H NMR degradation results of
synthesized polymers.
Polymer

Gd3+
Content
(%, w/w)a

Z-average
Diameter
(nm)b

PDIb Time to Theoretical
Fully
Mn
c
Degrade (kg/mol)d

L-PGAm-DTPA-Gd-T

25

21.7 ± 0.6

0.4

~1 month 139

L-PGAM-DTPA-Gd-MMT

27

28.5 ± 0.5

0.5

~8 h

145

L-PGAm-DTPA-Gd-BOM

25

23.8 ± 0.2

0.4

N/A

162

H-PGAm-DTPA-Gd-T

20

34.2 ± 0.8

0.3

~14 days

238

H-PGAm-DTPA-Gd-MMT

20

31.0 ± 0.5

0.3

~4 h

218

57

a

Determined by ICP-MS. Relative percent difference between duplicate samples: < 20%.
Relative percent difference between matrix spike and matrix spike duplicate recoveries: < 20%.
b
Determined by DLS
c
Determined by 1H NMR spectroscopy – polymer without Gd
dCalculated using metal content from ICP-ms and functionalization %
Low weight = +99%
High weight = ~83%
DLS studies were conducted at physiological temperature in saline to determine the hydrodynamic
diameters and size distributions of the PGAm-DTPA-Gd chelates. These measurements only
provide an approximate indication of size, as the chains are linear and would be expected to assume
random coil conformations in solution rather than behaving as ideal spherical structures.
Nevertheless, they were of interest as it is generally considered that a diameter >10 nm is required
to avoid immediate renal clearance after injection into the vasculature. 29 H-PGAm-DTPA-Gd-T
and H-PGAm-DTPA-Gd-MMT had the largest Z-average diameters at 34.2 ± 0.8 and 31.0 ± 0.5
nm respectively (Table 2.2, Figure 2.4A). All three of the low molar mass polymers had smaller
Z-average diameters, but they were still greater than 10 nm. Nevertheless, the Z-average diameter,
which is derived directly from the scattered light intensity tends to emphasize larger species, and
it is apparent from the volume distributions that a substantial portion of the lower molar mass
polymers had diameters on the order of 10 nm, whereas those of the high molar mass polymers
were above 10 nm. The variations of the diameters were also examined over the course of 1 h, and
were found to be minimal, showing that the molecules do not aggregate over time (Figure 2.4B).
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.
Figure 2.4. A) DLS volume distribution for different end-capped PGAm-DTPA-Gds. B) Zaverage time-course stability of polymers in saline at 37 °C measured by DLS.

2.3.4 In vitro Toxicity
DTPA has a history of use in medicine and extensive studies have been performed on its in vivo
toxicity.10, 30 Nevertheless, prior to intravenous administration, the synthesized contrast media was
evaluated for its potential cytotoxicity using MTT assays. Mouse myoblast cells were used as they
are common cell line for cytotoxicity studies. The polymers were incubated with the cells for 24
h. All of the polymers resulted in about 75% viability or higher at concentrations up to 0.25 mg/mL
(Figure 2.5A,B). Based on these results, the five polymers appear to be relatively non-toxic. While
the contrast media would be injected at a higher concentration, the concentrations used in these
MTT assays are more indicative of the expected tissue concentrations that could arise after dilution
upon injection, followed by distribution throughout the body. The observed toxicity at higher
concentrations may arise from some Gd3+ leaching from of the chelates during the 24 h incubation,
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which has been previously reported to result in cytoxicity for Gd 3+ chelates.31 In the ideal case,
degradation of the polymer and excretion of the chelates should occur prior to the release of free
metal ions in vivo.

Figure 2.5. A) MTT assay cell viability of the 3 different low-weight end-capped polymers at
varying concentrations. B) MTT assay cell viability of the 2 different high-weight end-capped
polymers at varying concentrations.

2.3.5 Maximum Gadolinium Concentration Determined by Micro-CT
Micro-CT was used to assess the gadolinium concentrations of polymer solutions when prepared
at high concentrations. Quantitative measurements are an inherent property of radiographic
imaging, where an element’s concentration exhibits a linear relationship with x-ray attenuation
coefficient. This property can be used post-imaging to determine metal concentrations in a sample.
Using the measured HU values of the standards and the samples, it was determined that L-PGAmDTPA-Gd-T and L-PGAm-DTPA-Gd-BOM polymers could be concentrated to a maximum of
approximately 64.7 ± 0.5 mg Gd/mL and 69.2 ± 0.1 mg Gd/mL. These values correspond to 259
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mg of L-PGAm-DTPA-Gd-T and 277 mg of L-PGAm-DTPA-Gd-BOM. This isn’t as high as we
obtained in previous work with gadolinium for micro-CT vascular imaging (100 mg/mL), 22, 32
which can be attributed to the substantial mass fraction of the material contributed by the polymer
backbone and chelate and viscosity challenges associated with polymer solutions. The viscosity
challenges were more significant for the higher molar mass polymers, resulting in a maximum
possible concentration of 49.2 ± 0.2 mg Gd/mL (248 mg chelate) and 61.7 ± 0.5 mg Gd/mL (309
mg chelate) for H-PGAm-DTPA-Gd-T and H-PGAm-DTPA-Gd-MMT. The high amount of
MMT-capped polymer that was able to dissolve is a direct result of its rapid degradation during
preparation.

2.3.6 In vivo Imaging
In preliminary in vivo studies, one mouse was injected with L-PGAm-DTPA-Gd-BOM (0.2 mL,
69.2 ± 0.1 mg Gd/mL) and an additional mouse with L-PGAm-DTPA-Gd-T (0.2 mL, 64.7 ± 0.5
mg Gd/mL). Both animals responded well to the contrast media, surviving over 1-month postinjection, and returning to their initial body weights (Figure A1.41). While the contrast media
appeared to be acceptable from a toxicity perspective, the presence of a noticeable amount of metal
in the bladder immediately after injection, even for these slowly degrading T and BOM end-capped
polymers, indicated that their hydrodynamic diameters were likely too low to clear the renal
threshold. Therefore, further in vivo studies focused on the high molar mass polymers H-PGAmDTPA-Gd-T and H-PGAm-DTPA-Gd-MMT.
Three-dimensional micro-CT images of 6 mice (n = 3 per polymer) were obtained prior to
intravenous administration of the contrast agents and at multiple time points following
administration of the agents. Each animal was re-positioned and monitored after injection before
post-injection imaging, and each scan took 16 s to acquire. The mice tolerated the media well and
only experienced a period of lethargy when waking up after the initial first hour of anesthesia and
imaging, possibly from metabolizing the contrast media or from the extended exposure to
anesthesia.33 After administration of the contrast agent, all major blood vessels and organs became
visible including the different parts of the heart (myocardium, ventricles, etc.), the aorta, and the
vena cava (Figure 2.6). ROIs 450 × 450 × 150 µm were taken 3 times in organs of interest, and
values were averaged between measurements before being averaged between mice. The mice were
imaged over a total period of four weeks, and an appreciable weight loss of 9.2%, ~2.4 g (Figure
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A1.41) was observed on the first day post injection. By the four-week point, all mice showed
weight gain ranging from 2.6 – 7.3% of initial body weight, and statistical analysis confirmed a
non-significant relationship between formulations.

Figure 2.6. Coronal (A, B) and sagittal (C) micro-CT images of a mouse 5 min post administration
of H-PGAm-DTPA-Gd-MMT, with some regions of interest added to identify different structures.
LV, Left ventricle; My, myocardium; L, liver; B, bladder; K, kidney; S, spleen; Ao, abdominal
aorta; VC, vena cava; Ce, celiac artery. Window = 1200, level = 335.
Both contrast agents demonstrated the ability to remain in the blood pool for the target time of 60
min (Figure 2.7), although H-PGAm-DTPA-Gd-MMT showed a more rapid decline in blood pool
enhancement than H-PGAm-DTPA-Gd-T, and both contrast agents showed a gradual decline in
blood pool enhancement over the course of an hour. As designed, while the trityl-capped polymer
showed no observable localization in the bladder, the MMT-capped samples showed obvious
accumulation in the bladder during the first few hours after injection as the polymer depolymerized
to form small molecule monomeric Gd3+ chelates, which were readily excreted via the kidneys.
Contrast enhancement in the liver was observed in the first image following injection, evident by
the slightly enhanced organs outline.
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Figure 2.7. Representative coronal micro-CT showing the heart (myocardium and LV), liver,
bladder, external jugular veins (double arrow) and the axillary veins (yellow arrows) for mice
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injected with A) H-PGAm-DTPA-Gd-T and B) H-PGAm-DTPA-Gd-MMT. The red arrows
pointing to the bladder are shown to draw attention to the fact that there is significant enhancement
in the bladder as the MMT end-capped polymer depolymerized, whereas such bladder
enhancement was not observed for the more stable T end-capped polymer. All times are reported
from the completion of contrast agent administration.
Quantitative analysis revealed an increase in blood pool CT number over 160 HU compared to
pre-contrast values (Figure 2.8). H-PGAm-DTPA-Gd-T and L-PGAm-DTPA-Gd-MMT both
showed similar liver enhancement by the one-hour mark at 58 ± 10 HU and 54 ± 11 HU
respectively. Alternatively, the spleen displayed somewhat different enhancement for both
samples, plateauing at 36 ± 1 HU above pre-contrast for the T end-capped polymer, and 67 ± 10
HU above pre-contrast for the MMT-capped sample. Analysis of the bladder is the most indicative
of the differing biodistribution of the two different samples, where H-PGAm-DTPA-Gd-T showed
negligible image enhancement and H-PGAm-DTPA-Gd-MMT CT numbers increased by 397 ±
70 HU. Maximum values at the one-hour time point for bladder enhancement reached 707 ± 156
HU above pre-contrast for the MMT-capped contrast agent, but these values reflect contrast media
that has settled in the bladder and are not taken as the mean for the ROI analysis. Notably, HPGAm-DTPA-Gd-MMT cleared from the blood pool faster when compared to H-PGAm-DTPAGd-T, with almost no contrast media left in the blood pool by 4 hr. This decrease is visibly
noticeable — blood pool enhancement values (taken in the aorta) are only 25 ± 7 HU for MMT
end-capped contrast agent while the T end-capped contrast media still showed 122 ± 12 HU of
enhancement that didn’t fully return to normal until the 24-hour point. Myocardium enhancement
was minimal for both formulations and subsided quickly.
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Figure 2.8. Time versus CT enhancement of measured tissues, where the orange line (squares)
represents H-PGAm-DTPA-Gd-MMT and the blue line (circles) represents H-PGAm-DTPA-GdT. Each organ has two associated graphs, the top being the first hour of imaging and the bottom is
the measurements over the course of 28 days. Statistical analysis compared significance between
the repeated HU measurements and different formulations over the entire time period. All values
were considered statistically insignificant (p > 0.05) except the bladder and the aorta.
The mice responded remarkably well to the contrast agents over the 28 days of the experiment,
regaining their initial weight after an 18–20-day period with no reportable health problems (Figure
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A.41). All animals survived until they were euthanized at 4 weeks. The slight increase in CT
number of the liver for both formulations can be attributed to either the immediate processing of
the contrast agents by the hepatobiliary system or is just a result of the liver being highly
vascularized,22, 32 but the large jump in CT number in the bladder for H-PGAm-DTPA-Gd-MMT
tells us that the degradation products are being excreted through the kidneys. This was as expected
given the rapid degradation of the MMT end-capped polymer (~4 hr). Although the trityl-capped
formulation was used as a comparative control, it still showed some enhancement in the bladder
over the course of the first hour of imaging. The similar enhancement of the spleen and liver for
both formulations for the first hr, was unexpected. Given the high molar mass and linear structure
of these contrast agents, the retention of the media in the liver and spleen are not ideal but this
relationship between high-molecular weight and longer retention has been demonstrated
previously.11 With this said, the maximum enhancement values for the liver and spleen are larger
for trityl-capped samples, demonstrating that a larger portion of the material was removed by the
kidneys for the MMT-capped formulation. The decrease in blood pool enhancement was exactly
what was desired, with the agent successfully remaining in circulation for one hour before being
almost entirely filtered/metabolized out of the blood pool.
Histological analysis of excised clearance organs including the liver, kidney and spleen of control
mice and mice injected with H-PGAm-DTPA-Gd-T and H-PGAm-DTPA-Gd-MMT indicated no
differences (Figure 2.9). Qualitatively, all images demonstrated comparable densities of cell nuclei
and a lack of basophilic material in the cytoplasm, indicating that these organs were healthy when
the animals were euthanized. Given the rapid clearance of the material from the bodies of the mice,
it could be theorized that any immediate, short-term damage may have recovered by the time the
animal was euthanized. With this said, any lasting negative effects from the new contrast agents
would have been apparent by the 28-day time point, suggesting the new contrast agents have low
toxicity when injected at the doses presented here.
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Figure 2.9. Representative histology images of clearance organs for control mice and mice
injected with the contrast agents. Organs were excised at 28 days and staining was performed with
haematoxylin and eosin. The scale bar in the kidney control section applies to all images.
Two major limitations still exist within these contrast agents. First, while DTPA is inexpensive for
these development experiments, in practice the ideal chelating molecule would be a macrocyclic
chelator. Macrocyclic chelators have been shown overall to have better binding stability and to
lead to fewer adverse reactions in patients.10, 30 The drawback to working with macrocylic chelates
is that they often require much longer to fully chelate the Gd3+,7 which could be problematic for
the rapidly depolymerizing MMT end-capped polymer. This aspect relates to the second limitation,
which involves the challenge of working with rapidly depolymerizing systems, which can break
down prematurely during their preparation or during injection. While the agents are moderately
stable when stored in a normal freezer (at least 1 month without noticeable degradation), to
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facilitate the synthesis and storage, it would still be beneficial to have an agent that only begins to
depolymerize upon injection in vivo.
Overall, this initial proof-of-concept experiment has demonstrated that these SIP-based Gd 3+chelating micro-CT contrast agents can be synthesized, tuned for specific degradation times, and
allow for targeted excretion of the molecule. The molecules exhibited sufficient metal
concentration to be visible in CT in vivo, and demonstrated stealth properties that allowed for
imaging of the vasculature for at least 1 hr. While we did not achieve metal concentrations as high
as those previously reported,22, 32 we were able to achieve effective excretion of the agents via the
kidneys, which is critical for decreasing the toxicity of these high dose contrast agents.

2.4

Conclusions

In this study we successfully synthesized novel, degradable micro-CT vascular contrast agents. By
comparing different polymer lengths and different end-caps, we created a small library of stimuliresponsive, degradable poly(chelates) that depolymerize under physiological conditions (pH 7.4),
and following preliminary in vivo experiments, identified the need for hydrodynamic diameters >
10 nm and a molar mass > 39 kg/mol for the initial PEtG. H-PGAm-DTPA-Gd-T and H-PGAmDTPA-Gd-MMT were evaluated in vivo, confirming that the synthesized contrast media can be
used to target excretion by the kidneys, reducing the retention of the agent in vivo, which could
lead to toxicity issues. At a dose of 0.2 mL per mouse (H-PGAm-DTPA-Gd-T = 49.2 ± 0.2 mg
Gd/mL and H-PGAm-DTPA-Gd-MMT = 61.7 ± 0.5 mg/mL Gd), both contrast media formulations
increased micro-CT image enhancement (at 80 kvP) by approximately 160 HU above pre-contrast
HU values, sustaining over 100 HU for over an hour. All animals survived until euthanasia at 4
weeks, which along with histological analysis of clearance organs, showed the low toxicity of the
agents. Beyond the optimizations that could improve these SIP-based contrast media for microCT, this system could be adapted for MRI given the low concentration of contrast material
required. Additionally, this system could be applied for vascular drug delivery applications given
its extended half-life in the blood. Future studies will explore the use of different chelating
molecules alongside different imaging modalities.
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Chapter 3
3
Long-circulating NaGdF4 Nanoparticles Encapsulated in a
Degradable Polymer for Microcomputed Tomography of the
Vasculature
3.1

Introduction

Most micro-computed tomography (micro-CT) and clinical CT contrast agents are based on
iodinated molecules, such as the commercially available pre-clinical contrast agents Fenestra VC
and LC, and clinical Iopamidol.1-3 As nanotechnology has advanced, efforts have expanded to
develop contrast agents composed of higher-density attenuating elements in nanoparticle (NP)
form, with formulations such as gold NP-based AuroVist 15 nm, which has 200 mg Au/mL. 4
Although gold can provide more contrast than iodine,5 its high k-edge of 80.7 keV is not ideal
since it is difficult to produce X-rays above the k-edge on most micro-CT scanners (average energy
range 30-90 keV). This inherent trait makes specialized imaging techniques such as dual-energy
micro-CT (DEMCT) difficult. Attempts to use attenuating materials with elements such as bismuth
(k-edge = 90.5 keV) or tantalum (k-edge 67 keV) NPs have been successful, but have also seen
limitations due to a range of problems including aggregation, low contrast, and hydrophobic
coatings.6, 7
Lanthanide metals are of interest as contrast agents for DEMCT as they have k-edges that lie within
the average micro-CT imaging energies. Previous work from our groups has proven that lanthanide
NPs can be used in micro-CT imaging. For example, NaGdF4 NPs were coated in various diblock
copolymers or functionalized with poly(ethylene glycol) (PEG), to create high concentration (100
mg Gd/mL) contrast agent formulations. While capable of successfully circulating for the times
required for vascular micro-CT imaging (~1 hr), there was a tendency for the NPs to localize in
reticuloendothelial system (RES) organs after being removed from the blood. 8 Additionally,
dialysis experiments have shown that the NPs can release Gd 3+ ions gradually over time under
physiological conditions.9 As a whole, the contrast agent wasn’t toxic, but there is a need to address
safe excretion of these particles. The purpose of developing a new contrast agent for micro-CT is
to help researchers to perform longitudinal imaging studies without the need to euthanize animals.
Therefore, repeated injections of NP agents that are not cleared from the body presents a problem.
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Research has shown that particles with a diameter of 10 nm or less can be safely excreted via the
kidneys, presenting a possible route to help optimize these polymer-nanoparticle systems. 10
Furthermore, advances in polymer science have brought exciting new molecules like selfimmolative polymers (SIPs) into biomedical research. SIPs are a type of degradable polymer, that
depolymerize fully when exposed to conditions that result in the cleavage of an end-cap. Poly(ethyl
glyoxylate) (PEtG) is a non-toxic, tunable SIP that has shown promise in fields such as tissue
engineering and drug delivery.11-15 By incorporating PEtG into a NP system we can change and
tune the polymer-NP system’s degradation rate and stimulus required to initiate the degradation
process by tuning the SIP end-caps.
This chapter describes an attempt at optimizing our previous design, using both 10 nm diameter
NPs and a SIP coating. We hypothesized that after injection the polymer-coated NPs would start
to degrade, releasing small GdNPs that could be safely excreted via the kidneys. PEtG was
synthesized with two different endcaps, alkynyl trityl (AT) and alkynyl methoxy trityl (AMT), due
to their degradation at different rates under physiological conditions (i.e., pH 5- 7.4), with the
AMT system degrading more rapidly than the AT system. 12 Quantification of the metal content of
the polymer-coated NPs via micro-CT is also described.

3.2

Experimental

3.2.1 General Materials
Gadolinium chloride hexahydrate, ammonium fluoride, oleic acid, cyclohexane, ethyl glyoxylate
and CuSO4 were purchased from Alfa Aesar (Ward Hill, MA). Centrifuge dialysis tubes (15 mL,
50 kDa MWCO), sodium ascorbate, deuterated chloroform, 4-(2-propyn-1-yloxy) trityl chloride,
and 4-(2-propyn-1-yloxy)-4’-methoxytrityl chloride were purchased from Millipore Sigma
(Oakville, ON).

Sodium hydroxide, methanol, hexane, tetrahydrofuran (THF), and N,N-

dimethylformamide (DMF) were purchased from Caledon Laboratories (Georgetown, ON).
Ethanol was purchased from Commercial Alcohols (Tiverton, ON). 1-Octadecene was purchased
from Acros Organics (Geel, Belgium). Spectra/Por 6 dialysis tubing (50 kDa MWCO) was
obtained from Spectrum Laboratories (Rancho Dominguez, CA). PEG-N 3 (5 kDa) was synthesized
according to literature.16 AT and AMT capped PEtG were synthesized following a published
procedure17 and end-capped using the procedure mentioned below.
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3.2.2 General Methods:
The diameters of the NPs and polymer-coated NPs were measured by dynamic light scattering
(DLS) using a Zetasizer Nano ZS instrument (Malvern Instruments Ltd, Malvern UK) at room
temperature (25°C) in a quartz cuvette (1 mg/mL). Thermal degradation studies were performed
using a Q600 SDT thermogravimetric analysis instrument (TA Instruments, Canada).
Transmission electron microscopy (TEM) was performed with a Philips CM10 (Philips,
Amsterdam) using an acceleration voltage of 80 kV. 1 mg of the sample was prepared in 1 mL of
water and then a single drop was deposited onto a formvar/copper grid to be air dried overnight.
Fourier transform-infrared (FT-IR) spectra were recorded using a PerkinElmer Spectrum Two FTIR spectrometer with an attenuated total reflectance (ATR) attachment and a single reflection
diamond. Centrifugation was performed in 50 mL centrifuge tubes using a VWR Clinical 200
centrifuge with a 28° fixed rotor angle. 1H (400 MHz) nuclear magnetic resonance (NMR) spectra
were obtained using a Bruker AvIII HD 400 (Milton, ON). 1H NMR chemical shifts were
calibrated against the residual solvent signal of CHCl 3 (7.26 ppm). Size exclusion chromatography
(SEC) was performed using a Gel Permeation Chromatography (GPC) instrument equipped with
a Viscotek GPC Max VE2001 solvent module. Samples were analyzed using the Viscotek VE3580
RI detector operating at 30°C, and triple detection Malvern 270 Dual detector. The separation
technique employed two Agilent Polypore (300x7.5mm) columns connected in series and to a
Polypore guard column (50x7.5mm). Samples were dissolved in THF (glass distilled grade) at
approximately 5mg/mL concentrations, filtered through 0.22 µm syringe filters and injected using
a 100 µL loop. The THF eluent was filtered and eluted at 1 mL/min for a total of 30 min. A
calibration curve was obtained from PMMA standards with molecular weight ranges of 690 –
790,000 g/mol.

3.2.3 Synthesis of Poly(ethyl glyoxylate)s
Synthesis of PEG113-N3. PEG113-N3 was synthesized using a published procedure.16 1H NMR
(CDCl3, 400 MHz): δ 3.62 (453H, s), 3.36 (br s, 3H). 13C {1H} NMR (CDCl3, 100 MHz): δ 70.3.
FT-IR: 2883 cm-1. SEC (THF, PMMA): Mn = 5.4 kg/mol, Mw = 6.0 kg/mol, Đ = 1.10
Synthesis of PEtG-AT. To 60 mL of dried toluene in a Schlenk flask under N2, n-butyl lithium
solution was added (0.43 mL, 0.60 mmol, 1.0 equiv). Purified ethyl glyoxylate (15 mL, 150 mmol,
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250 equiv) was subsequently added and the entire polymerization mixture was cooled to −20 ºC.
In a separate flask, 4-(2-propyn-1-yloxy) trityl chloride (0.68 g, 2.0 mmol, 3.3 equiv) and silver
triflate (0.52 g, 2.0 mmol, 3.3 equiv) were placed and the flask was evacuated and purged with N 2.
A 5.0 mL aliquot of dried toluene was added, and the flask contents were mixed at 70 ºC for 1 h
to yield the end-cap mixture. After 30 min, dried NEt3 (0.59 mL, 4.2 mmol, 7.0 equiv) was added
to the polymerization flask. After 1 h, the contents of the end-cap mixture flask were cooled to
−20 ºC before 20 mL of dry CH2Cl2 were added and the mixture was pipetted into the
polymerization flask. The polymerization flask was then capped and closed off from the N 2 line
before being allowed to warm to room temperature overnight. Purification was achieved by
concentrating the polymerization mixture and precipitating it in 660 mL of a 10:1 MeOH:water
mixture. After decanting, the purified residue was dissolved in CH 2Cl2, mixed with activated
charcoal, and filtered through Celite before being concentrated to afford 5.1 g of an orange tacky
solid. Yield = 33%. 1H NMR (CDCl3, 400 MHz): δ 5.46 –5.74 (m, 170H), 4.67 (s, 2H), 4.22 (s,
340H), 2.54 (s, 1H), 1.28 (s, 540H), 0.87 (br s, 3H). 13C {1H} NMR (CDCl3, 100 MHz): δ 165.7,
128.0, 91.8–94.58, 62.2, 14.0. FT-IR: 2985, 1750 cm-1. SEC (THF, PMMA): Mn = 16.8 kg/mol,
Mw = 22.4 kg/mol, Đ = 1.33
Synthesis of PEtG-AMT. PEtG-AMT was synthesized using the same procedure as PEtG-AT
except 4-(2-propyn-1-yloxy)-4’-methoxytrityl chloride (0.58 g, 1.6 mmol, 2.7 equiv) was used
with silver triflate (0.41 g, 1.6 mmol, 2.7 equiv) in the end-cap mixture and the polymerization
utilized a lower volume of dry NEt3 (0.51 mL, 3.7 mmol, 6.2 equiv). After purification, 7.2 g of a
yellow tacky solid was afforded. Yield = 47%.1H NMR (CDCl3, 400 MHz): δ 5.46–5.72 (m,
170H),4.65 (s, 2H), 4.21 (s, 340H), 2.53 (s, 1H), 1.29 (s, 540H), 0.83 (br s, 3H). 13C {1H} NMR
(CDCl3, 100 MHz): δ 166.0, 92.0–94.8, 62.5, 14.3. FT-IR: 2985, 1749 cm -1. SEC (THF, PMMA):
Mn = 16.8 kg/mol, Mw = 22.4 kg/mol, Đ = 1.26

3.2.4 Synthesis of PEtG-PEG diblock copolymers
Synthesis of PEtG-AT-PEG. Previously synthesized AT-PEtG was linked to PEG113-N3 via a
copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction using a previously published
procedure.12 PEtG-AT ( 325 mg, 0.02 mmol, 1.0 equiv.) and PEG (260 mg, 0.05 mmol, 2.5 equiv.)
were dissolved in DMF (10 mL, 1:100 v/w PEtG). The solution was placed under vacuum before
being purged with Ar for 1 hr. CuSO4 (2.9 mg, 0.020 mmol, 1.0 equiv.) and sodium ascorbate (3.6
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mg, 0.020 mmol, 1.0 equiv.) were added and the solution was elevated to 40 ºC for 16 h. The
solution was then transferred to a regenerated cellulose dialysis membrane with a 50 kg/mol
MWCO and dialyzed against deionized water for 16 hr ( 5 L, 2 solvent changes) to remove excess
PEG and DMF. The dialyzed solution was then frozen and lyophilized. The resulting solid material
was then broken into small pieces by physical agitation in 15 mL of deionized water and
centrifuged at 6000 rpm for 15 min. This wash process was completed 3 times and the final
sedimented material was lyophilized, leaving a white, rubbery product. (332 mg, Yield = 79%).
H1 NMR (400 MHz, CDCl3): δ 5.46–5.73 (m, 170H), 4.55 (s, 2H), 4.21 (s, 340H0, 3.64 (s, 452H),
1.29 (s, 510H). 13C {1H} NMR (CDCl3, 100 MHz): δ 165.7, 92.0–94.3, 70.7, 62.2, 13.9. FT-IR:
2985, 2916, 1748 cm-1. SEC: Mn = 19.8 kg/mol, Mw = 25.2 kg/mol, Đ = 1.27
Synthesis of PEtG-AMT-PEG. PEtG-AMT-PEG was synthesized using the same procedure as
PEtG-AT except that PEtG-AMT was used as the starting material. Yield = 72%. H 1 NMR (400
MHz, CDCl3): δ 5.45–5.73 (m, 170H), 4.55 (s, 2H), 4.22 (s, 340H), 3.64 (s, 452H), 1.29 (s, 510H).
13

C {1H} NMR (CDCl3, 100 MHz): δ 165.4, 91.5–94.2, 70.4, 61.9, 13.6. FT-IR: 2985, 2889 1748

cm-1. SEC: Mn = 16.3 kg/mol, Mw = 20.5 kg/mol, Đ = 1.26

3.2.5 Preparation of Polymer-Coated Nanoparticle Assemblies
Synthesis of 10–20 nm Diameter Oleate-coated NaGdF4 NPs (GdNPs). GdNPs 10 nm in
diameter were synthesized by modifying a previously reported procedure. 9,

18-20

Gadolinium

chloride hexahydrate (2325 mg, 6.25 mmol, 1.0 equiv.), oleic acid (100 mL) and 1-octadecene (90
mL) were magnetically stirred and subjected to high vacuum. This mixture was heated to 120 °C
for 1 hr. to remove water, then cooled under argon to 50 °C. Ammonium fluoride (937.5 mg, 25
mmol, 4.0 equiv.) and sodium hydroxide (625 mg, 15.625 mmol, 2.5 equiv.) were each dissolved
in 30 mL methanol before being mixed, briefly sonicated and then injected into the mixture. The
mixture was sustained at 50 °C during injection and for no less than 30 min afterwards to promote
nucleation. The mixture was then heated to 65 °C under vacuum for 30 min to remove methanol,
then 100 °C for 30 min to remove water. The solution was then placed under an argon atmosphere
and heated at approximately 10 °C/min to 300 °C. This temperature is sustained for 30 min before
the mixture was cooled to room temperature for purification. GdNPs were precipitated by adding
35 mL of ethanol to 15 mL of the reaction solution and centrifuging at 6000 rpm for 30 min. The
supernatant was decanted, the GdNPs were redispersed in THF, and the solution was centrifuged
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for an additional 30 min. Precipitated GdNPs were dried under vacuum overnight before being
stored at room temperature. Yield = 92%. Yield was confirmed by thermal gravimetric analysis
(TGA), where comparable composition measurements to previous nanoparticle batches was used
as a reference. This composition is approximately 20% oleate coating and 80% NaGdF 4
nanocrystals.
Nanoprecipitation for Self-Assembly of Polymer Nanoparticles Containing Gadolinium
Nanoparticles. GdNPs (10 mg) were dissolved in 0.25 mL of THF. In a separate vial, PEtG-ATPEG (10 mg, 0.51 µmol, 1:1 mass ratio) was dissolved in 0.25 mL of THF. These solutions were
then combined and added dropwise to 5.0 mL of deionized water under magnetic stirring. After 1
hour of stirring under a steady air-flow to remove THF, the solution was purified using centrifugal
dialysis against deionized water (6×15 mL 50 kDa MWCO tubes, 6000 rpm, 15 min) until the
solution was ultra-concentrated. At this point, the contrast media molecule can also be referred to
as an assembly. Lyophilization of the product allowed for yield calculations but may not be entirely
accurate given the rubbery product leftover, as it is difficult to redissolve in water. This procedure
was repeated with PEtG-AMT-PEG, and at a mass:NP ratio of 2:1 for both polymers.

3.2.6 General Micro-CT Imaging Methods
Micro-CT images of acrylic phantoms were acquired with the GE eXplore speCZT (London,
Canada) with a single 5-minute rotation scan protocol. Images were acquired with 900 views
(0.33 ms per view) at 90 kVp, 40.0 mA (16 ms exposure) over 360° and reconstructed using a
cone-beam reconstruction algorithm. The final images have a voxel size of 50 x 50 x 50 µm.
Images were examined using Microview (Parallax Innovations, Canada) and CT contrast was
measured in Hounsfield Units (HU is a dimensionless, standard, linear scale of X-ray attenuation
coefficient measured in CT, where water = 0 HU and air = −1000 HU). All HU values were
obtained by averaging the values within a region of interest that was 450 × 450 × 150 μm.

3.2.7 Micro-CT Imaging of Concentrated Contrast Media
The relationship between gadolinium concentration and HU was determined through the
construction of a standard curve. Gadolinium chloride was diluted in saline at concentrations of 5,
10, 20, 50 and 100 mg/mL and HU values were determined. The linear regression between metal
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concentration and CT number was then used to determine gadolinium concentrations in each of
the highly concentrated samples.

3.3

Results and Discussion

3.3.1 Polymer Synthesis
PEG113-N3 (5 kg/mol) was synthesized using a published procedure.16 SEC and NMR data were in
good agreement regarding the molar mass (Table 3.1). Poly(ethyl glyoxylate)s with two different
end-caps were used as starting polymers for this work (Scheme 3.1). Similar to Chapter 2, this
work used trityl (T) and monomethoxytrityl (MMT)-based end-caps, but the end-caps used in this
chapter were also functionalized with a propargyl group for the CuAAC click reaction. Both
molecules were targeted to be around ~15 kg/mol and ended up at ~17 kg/mol; the similar Mn
means that any differences in assembly behavior of the two polymers cannot be attributed to
differences in molar masses.
Table 3.1. SEC Data for the PEtGs and PEtG Diblocks
Polymer

Mn (kg/mol)

Mw (kg/mol)

Đ

PEG113-N3

5

6

1.1

PEtG-AT

17

22

1.3

PEtG-AMT

17

22

1.3

PEtG-AT-PEG

20

25

1.3

PEtG-AMT-PEG

16

25

1.3
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Scheme 3.1. Synthesis of PEtG-PEG diblock copolymers with AT and AMT linker end-caps.
The click reaction was successfully performed by adding CuSO4 and sodium ascorbate into a
vessel with the PEtG and PEG in DMF at 50 °C overnight. The resulting material was a rubbery,
white mass when purified. 1H NMR spectroscopy confirmed the linking of the PEG polymer block
to the PEtG block by the appearance of peak “1” at ~ 3.62 ppm, corresponding to the PEG
backbone (Figure 3.1c). An additional means of confirming the linkage via 1H NMR was the
disappearance of the CH peak associated with the alkyne at ~ 2.5 ppm (Figures A2.2-2.5). 1H NMR
spectroscopy molecular weight calculations were in agreeance with values obtained by SEC.
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Figure 3.1. Stacked 1H NMR spectra of synthesized polymers: PEtG-AT, PEG 113-N3, PEtG-ATPEG (CDCl3, 400 MHz). The blue star indicates solvents such as dichloromethane and CDCl 3.
The resulting diblock copolymers were also characterized with FT-IR and 13C NMR spectroscopy,
as well as SEC. FT-IR spectroscopy indicated a successful linkage given the appearance of a CH stretch at ~ 2880 cm-1, corresponding to the CH2 groups in the PEG backbone (Figure 3.2), peaks
such as the ester C=O stretch (1750 cm-1) corresponding to PEtG, and the absence of an azide
stretching peak (2100 cm-1) that was initially present in the PEG, but which should disappear upon
conjugation as the azide was converted to a triazole.
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Figure 3.2. Representative FT-IR spectra of synthesized diblock copolymers, shown for the ATcapped sample.
The 13C NMR spectra confirmed the presence of PEtG, based on the backbone methine peak (91–
95 ppm), as well as PEG, based on its CH2 peak (~70 ppm) (Figures A2.9 and A2.10). Most
importantly, SEC data confirmed that there were no unreacted species present - namely that of
excess PEG which would appear right before the 17 min mark, as indicated by the orange arrow
had been removed (Figure 3.3). The SEC data present in Table 3.1 shows a slight decrease in Mn
for the AMT sample (17 to 16 kg/mol), but between the increase in Mw (22 to 25 kg/mol) alongside
the 1H and 13C NMR spectra and FTIR spectra, we are confident that these two molecules have
been successfully conjugated.
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Figure 3.3. Overlay of normalized SEC traces of various synthesized polymers (THF, PMMA).
The second peak associated with the orange trace indicates where excess PEG would have a visible
peak if present. The two peaks associated with PEG-N3 are due to dimerization.

3.3.2 Nanoparticle Synthesis
Oleate-coated NaGdF4 with metal core diameters in the 10–20 nm range were successfully
synthesized using a modification to a previous procedure (Scheme 3.2). 9, 18-20 The largest factors
in the reaction that influence diameter are the time the reaction is held at 50 °C after the
NaOH/NH4F addition and the time the reaction is held at 300 °C. The 50 °C period is crucial for
nucleation, and extending this time allows for more nucleation points to grow, leaving less material
for particle growth. The 300 °C portion is the step in which the particles continue to grow, and
extending this time can cause entirely different morphologies. 19 As the solution cools, the oleic
acid present in solution will start to form an oleate coating on the nanocrystals, resulting in oleatecoated NaGdF4 nanoparticles. DLS measurements of GdNPs in cyclohexane indicated a volumeaverage diameter of 19.1 ± 1.3 nm, Z-average diameter of 41.3 ± 0.3 nm, and a polydispersity
index (PDI) of 0.3 (Figure 3.4A). The range of metal core diameters, including many GdNP at and
around 10 nm in diameter, was confirmed by TEM (Figure 3.4B). Discrepancies in measurements
are due to the very small amount of nanoparticles that can be confirmed in the viewing frame of
the TEM versus the inherently larger particle count in DLS. Although not precisely 10 nm, the
mean, and subsequent majority in the size distribution fell in the 10–20 nm range , and this
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moderately disperse sample would serve as a proof-of-concept for the subsequent investigations.
The NPs were analyzed by thermogravimetric analysis to assess the oleate coating content, and
they were found to have an oleate content of ~ 20% (w/w), which is comparable to previous
particles synthesized by our group (Figure A2.13). 9

Scheme 3.2. Synthesis of oleate-coated NaGdF4 nanoparticles.
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Figure 3.4. A) Volume diameter distribution of GdNP in cyclohexane as measured by DLS. B) A
TEM image of the oleate coated NaGdF4 NP.

3.3.3 Polymer Self-Assembly and GdNP Encapsulation
The new synthesized diblock copolymers were first evaluated for their capability to form stable
nano-assemblies. DLS measurements of the empty PEtG-AT-PEG micelles in water indicated a
volume average diameter of 26.5 ± 1.0 nm, Z-average diameter of 34.4 ± 0.2 nm and a PDI of 0.1
(Figure A2.13). These results therefore demonstrated the capability of the amphiphilic diblock
copolymers to self-assemble in water. Following this success, GdNPs were encapsulated through
their dissolution into the THF phase and encapsulation during the assembly of the polymers. Both
1:1 and 2:1 polymer:GdNP ratios were investigated. Unfortunately, the assemblies were generally
isolated in low yield due to poor stability and subsequent aggregation. These aggregates were
filtered out during the isolation of the assemblies, leaving low concentration solutions (Table 3.2).
Interestingly, the PEtG-AMT-PEG encapsulation at a 2:1 ratio had a substantially higher yield at
than the rest of the systems (43%). Its DLS size distribution had a broader, almost bimodal
distribution with a peak at a lower diameter than the corresponding 1:1 preparation (Figure 3.5).
However, the Z-average diameter for this sample was a bit higher, presumably due to some
aggregation. On the other hand, for the PEtG-AT-PEG assemblies containing GdNPs, there was a
10 nm decrease in the Z-average diameter for the 2:1 compared to 1:1 samples, suggesting that the
2:1 ratio better stabilized the assemblies, which was expected. This can be attributed to the high
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SA:V that small nanoparticles have. As nanoparticles get smaller, this ratio increases, meaning
that for two equivalent masses of nanoparticles at different sizes, you will need more polymer to
adequately stabilize the smaller sized particles.

Table 3.2. Nanoparticle encapsulation yields, Z-average diameters and PDI
Polymer

PEtG-AT-PEG

Z-Average

Polydispersity Yield (%)

Diameter (nm)

Index

61.7 ± 0.7

0.3

17

73.8 ± 0.9

0.3

19

88.6 ± 0.4

0.2

17

77.1 ± 2.1

0.2

43

2:1
PEtG-AT-PEG
1:1
PEtG-AMT-PEG
2:1
PEtG-AMT-PEG
1:1

Figure 3.5. DLS volume distributions for A) PEtG-AT-PEG and B) PEtG-AMT-PEG
A limitation of previous nanoparticle-based research was the high viscosity of the contrast media,
imparting a limit on the concentrations of the assemblies that could be achieved (100 mg Gd/mL). 8,
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9

Before in vitro and in vivo characterization such as degradation studies or cell assays, we wanted

to ensure we could still achieve comparable metal concentrations when highly concentrating the
contrast media. Therefore, micro-CT was used to quantify the amount of gadolinium in the
assemblies. Unfortunately, the poor stability of the assemblies prevented high concentrations from
being obtained as much of the agent was filtered out before centrifugal dialysis purification. In
previous work, filtration post self-assembly removed aggregates that accounted for a small portion
of assemblies. In this system the bulk of the nanoparticles were poorly stabilized upon
nanoprecipitation, resulting in aggregation and subsequent removal by filtration (Figure 3.6). For
example, a sample prepared with the aim of achieving 200 mg Gd/mL, had less than 10 mg Gd/mL,
with some measurements indicating values below 0 HU (no detectable gadolinium). As a result, it
was realized that this system had been explored and exhausted, and would require substantial
additional synthesis alterations to improve the stabilities of the assemblies.

Figure 3.6. Micro-CT image of a phantom with varying concentrations of gadolinium chloride
and a prepared sample of “highly concentrated” 1:1 PEtG-AMT-PEG coated GdNP.

3.4

Conclusions

In this study we successfully synthesized GdNPs with a targeted diameter of about 10 nm, as well
as amphiphilic, self-assembling diblock copolymers composed of PEtG-PEG with different linker
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end-caps. While we demonstrated that this polymer system could encapsulate the NPs, the
resulting assemblies were unstable. This result can likely be attributed to challenges associated
with stabilizing the high surface area to volume ratios of these small GdNPs in the micelle core,
as well as possible incompatibilities between PEtG and oleate-coated GdNPs. Therefore, these
assemblies were not investigated for micro-CT imaging. The approach using small NPs that would
be excreted upon degradation of polymer assemblies could still potentially work, but it would
require further optimization of encapsulating polymers to increase the dispersibility and stability
of the system.
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Chapter 4
4

Conclusions and Future Work

Overall, this thesis presented the preparation of two novel, degradable, lanthanide-based contrast
agents. First, a novel approach to bridging the gap between computed tomography (CT) and
magnetic resonance imaging (MRI) contrast agents was explored by synthesizing a small library
of poly(chelate)s featuring a self-immolative polymer (SIP) backbone, poly(glyoxylamide)
(PGAm). Alterations in synthesis procedure were explored so that the poly(chelate) synthesis
could be optimized and two sizes of contrast agent were synthesized (hydrodynamic diameter >10
nm and <10 nm). End-caps with variable cleavage rates were also explored, resulting in new
insights regarding the degradation behavior of single vs double end-capped SIP, namely a doubling
in depolymerization rate when the polymer is fitted with a second end-cap. In vivo images were
acquired to test the contrast agents’ abilities to circulate in the blood pool for sufficient time and
then degrade to be excreted through the kidneys. This is a goal that was set with the use of SIPs so
that we could potentially facilitate clearance of the gadolinium-chelates and reduce the potential
for transmetallation.1-4 Testing to assess the release of metals in a dialysis setting, or to incorporate
mass spectrometry analyses of tissues could help confirm this for more serious pre-clinical drug
candidates. We were able to successfully increase the blood pool CT number by over 160 HU with
both of the synthesized higher molar mass polymers (hydrodynamic diameter >10 nm). Excitingly,
we were able to demonstrate targeted excretion of the more rapidly degradable contrast agent,
where the bladder of the mice injected with trityl-capped (T) samples had a negligible change in
CT number compared to the monomethoxy trityl-capped (MMT) samples, which increased by 397
± 70 HU. Additionally, blood pool CT numbers at the 4-hr. time-point were only enhanced by 25
± 7 HU for the MMT end-capped contrast agent while the T end-capped contrast media still
showed 122 ± 12 HU of enhancement, which didn’t normalize until 24-hr. The collective results
point to a successful proof-of-concept for our design involving the use of an SIP as a vascular
contrast agent with tunable excretion. A potential improvement on the existing design could
include the use of macrocyclic chelators such as DOTA, which are inherently more kinetically
stable and are generally accepted as being safer than linear chelators due to having fewer adverse
reactions in patients.5, 6 A challenge associated with macrocyclic chelators is the extended time it
takes to fully chelate Gd3+,7 which could be a problem with these rapidly degrading polymers. This
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also demonstrates a need for more end-caps that could allow for material to only undergo
degradation in vivo as opposed to throughout synthesis. As an example, a thermally-responsive
end-cap could theoretically benefit targeted drug release by allowing for thermal ablation at the
desired drug delivery region.
As discussed briefly in section 2.4, one of the more promising potential translations of this work
is to MRI. The quantity of contrast media required for MRI compared to micro-CT is much lower,
which would eliminate the associated challenges with high metal concentration required by microCT and the associated increase in viscosity. With this said, chemical modifications would need to
be performed to also influence the relaxivity (relaxivity is comparable to attenuating coefficient in
CT). Preliminary data not shown in this thesis illustrated that the current design has relaxivity
measurements very close to commercial Gd-chelate contrast agents, but our contrast media has a
completely different clearance profile. Synthesis alterations to better immobilize the complex
could increase relaxivity,8 or different complexed metals could also be explored. As an example,
manganese-porphyrins are an interesting new class of contrast agents, as they provide superior T 1
enhancement when compared to Gd-DTPA.9 These porphyrins can be functionalized with
carboxylic acid groups, which could allow the already established functionalization procedure to
be used.10 This route could successfully establish long-circulating MRI contrast agents that could
be safely excreted after extended periods of imaging, which is an exciting prospect.
An attempt to improve the Gillies/Drangova groups’ previous design 11,

12

of polymer-coated

NaGdF4 nanoparticles (NPs) showed initial promise, with the synthesized diblock copolymer’s
SEC data, NMR spectra and FT-IR spectra confirming a successful preparation of the targeted
polymers. The amphiphilic diblock copolymers self-assembled to form empty micelles, but when
NPs were introduced, the assemblies became unstable and aggregated. This instability resulted in
low yields of the assemblies, and subsequent phantom imaging confirmed that the vast majority of
nanoparticles had been filtered out of solution during the assembly isolation process. In the future,
for this system to function as designed, it is vital that the NPs continue to be synthesized at a
diameter of 10 nm or less to ensure excretion by the kidneys. 13 With this said, efforts such as large
surface-area-to-volume ratio (SA:V) is adequately dealt with. Additionally, changing the diblock
lengths of the 17 kg/mol hydrophobic poly(ethyl glyoxylate) (PEtG) chain and 5 kg/mol
poly(ethylene glycol) (PEG) could influence potentially improve the stabilities of the assemblies.
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For example, increasing the PEG:PEtG ratio may be helpful as PEG is quite effective in stabilizing
assemblies in solution. The compatibility of the hydrophobic block with the GdNPs could also
potentially be improved by changing the pendant ester groups to other alkyl groups such as butyl
or hexyl.

4.1

References

1.
Aime, S.; Caravan, P., Biodistribution of gadolinium-based contrast agents, including gadolinium
deposition. J. Magn. Reson. Imaging2009, 30, 1259-1267.
2.
Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C., Factors affecting the clearance and
biodistribution of polymeric nanoparticles. Mol. Pharm.2008, 5, 505-515.
3.
Nasongkla, N.; Chen, B.; Macaraeg, N.; Fox, M. E.; Fréchet, J. M. J.; Szoka, F. C., Dependence
of pharmacokinetics and biodistribution on polymer architecture: effect of cyclic versus linear polymers. J.
Am. Chem. Soc.2009, 131, 3842-3843.
4.
Idée, J. M.; Port, M.; Raynal, I.; Schaefer, M.; Le Greneur, S.; Corot, C., Clinical and biological
consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review.
Fundam Clin Pharmacol 2006, 20, 563-76.
5.
Behzadi, A. H.; Zhao, Y.; Farooq, Z.; Prince, M. R., Immediate allergic reactions to gadoliniumbased contrast agents: a systematic review and meta-analysis. Radiology 2018, 286, 731.
6.
Cowling, T.; Frey, N. Macrocyclic and Linear Gadolinium Based Contrast Agents for Adults
Undergoing Magnetic Resonance Imaging: A Review of Safety; CADTH Rapid Response Reports, 2019
7.
Sherry, A. D.; Caravan, P.; Lenkinski, R. E., Primer on gadolinium chemistry. J. Magn. Reson.
Imaging2009, 30, 1240-1248.
8.
Wahsner, J.; Gale, E. M.; Rodríguez-Rodríguez, A.; Caravan, P., Chemistry of MRI contrast
agents: current challenges and new frontiers. Chem. Rev.2019, 119, 957-1057.
9.
Alhamami, M.; Cheng, W.; Lyu, Y.; Allen, C.; Zhang, X.-A.; Cheng, H.-L., Manganeseporphyrin-enhanced MRI for the detection of cancer cells: A quantitative in vitro investigation with
multiple clinical subtypes of breast cancer. PloS one 2018, 13, e0196998-e0196998.
10.
Shi, L.; Jiang, Y.-Y.; Jiang, T.; Yin, W.; Yang, J.-P.; Cao, M.-L.; Fang, Y.-Q.; Liu, H.-Y.,
Water-soluble manganese and iron mesotetrakis(carboxyl)porphyrin: DNA Binding, oxidative cleavage,
and cytotoxic activities. Molecules 2017, 22.
11.
Cruje, C.; Dunmore-Buyze, J.; MacDonald, J. P.; Holdsworth, D. W.; Drangova, M.; Gillies, E.
R., Polymer assembly encapsulation of lanthanide nanoparticles as contrast agents for in vivo micro-CT.
Biomacromolecules 2018, 19, 896-905.
12.
Cruje, C.; Dunmore-Buyze, P. J.; Grolman, E.; Holdsworth, D. W.; Gillies, E. R.; Drangova, M.,
PEG-modified gadolinium nanoparticles as contrast agents for in vivo micro-CT. Sci. Rep.2021, 11, 16603.

92

13.
Choi, C. H.; Zuckerman, J. E.; Webster, P.; Davis, M. E., Targeting kidney mesangium by
nanoparticles of defined size. Proc. Natl. Acad. Sci. U S A 2011, 108 (16), 6656

93

Appendix 1: Chapter 2 Supplementary Figures
1

H NMR Spectra (for Characterization)

Figure A1.1. 1H NMR spectrum of L-PEtG-T (CDCl3, 400 MHz).
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Figure A1.2. 1H NMR spectrum of L-PEtG-MMT (CDCl 3, 400 MHz).

Figure A1.3. 1H NMR spectrum of L-PEtG-BOM (CDCl3, 400 MHz). The end-groups could not
be accurately integrated due to the presence of some uncapped polymer.
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Figure A1.4. 1H NMR spectrum of H-PEtG-T (CDCl 3, 400 MHz).

Figure A1.5. 1H NMR spectrum of H-PEtG-MMT (CDCl 3, 400 MHz).
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Figure A1.6. 1H NMR spectrum of L-PGAm-T (D2O, 400 MHz). The end-groups could not be
accurately integrated due to their broad, low resolution peaks

Figure A1.7: 1H NMR spectrum of L-PGAm-MMT (400 MHz, D2O). End groups could not be
accurately integrated due to rapid degradation of polymer.
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Figure A1.8. 1H NMR spectrum of L-PGAm-BOM (D2O, 600 MHz). The end-groups could not
be accurately integrated due to their broad, low resolution peaks

Figure A1.9. 1H NMR spectrum of H-PGAm-T (D2O, 400 MHz). The end-groups could not be
accurately integrated due to their broad, low resolution peaks
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Figure A1.10. 1H NMR spectrum of H-PGAm-MMT (D2O, 400 MHz). The end-groups could not
be accurately integrated due to the rapid degradation of the polymer
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Figure A1.11: 1H NMR spectrum of L-PGAm-DTPA-T (600 MHz, D2O). End groups could not
be accurately integrated due to high molecular weight of polymer. Due to the solvent, the only
visible protons are those of the 11 CH2 groups and single CH3 groups, totaling 25 H.
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Figure A1.12: 1H NMR spectrum of L-PGAM-DTPA-MMT (600 MHz, D 2O). End groups could
not be accurately integrated due to high molecular weight and rapid degradation of polymer. Due
to the solvent, the only visible protons are those of the 11 CH2 groups and single CH3 groups,
totaling 25 H. The slightly higher integration is attributed to DTPA-PGAm hydrate species from
the rapidly degrading polymer backbone.
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Figure A1.13: 1H NMR spectrum of L-PGAm-DTPA-BOM (400 MHz, D 2O). End groups could
not be accurately integrated due to high molecular weight of polymer. Due to the solvent, the only
visible protons are those of the 11 CH2 groups and single CH3 groups, totaling 25 H. The slightly
higher integration is attributed to uncapped polymer backbone, as BOM is inherently more difficult
to attach as an end-cap. These uncapped polymers will end up degrading, leaving some hydrate
peaks around 5.2-5.3 ppm.
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Figure A1.14: 1H NMR spectrum of H-PGAm-DTPA-T (600 MHz, D 2O). End groups could not
be accurately integrated due to high molecular weight of polymer. Due to the solvent, the only
visible protons are those of the 11 CH2 groups and single CH3 groups, totaling 25 H. The slightly
higher integration is attributed to DTPA-PGAm hydrate species from the rapidly degrading
polymer backbone.-
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Figure A1.15: 1H NMR spectrum of H-PGAm-DTPA-MMT (600 MHz, D 2O). End groups could
not be accurately integrated due to high molecular weight of polymer. Due to the solvent, the only
visible protons are those of the 11 CH2 groups and single CH3 groups, totaling 25 H. The slightly
higher integration is attributed to DTPA-PGAm hydrate species from the rapidly degrading
polymer backbone.
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13

C {1H} NMR Spectra

Figure A1.16. 13C {1H} NMR spectrum of L-PEtG-T (CDCl3, 100 MHz).

Figure A1.17. 13C {1H} NMR spectrum of L-PEtG-MMT (CDCl 3, 100 MHz)
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Figure A1.18. 13C {1H} NMR spectrum of L-PEtG-BOM (CDCl 3, 100 MHz)

Figure A1.19. 13C {1H} NMR spectrum of H-PEtG-T (CDCl3, 100 MHz)
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Figure A1.20. 13C {1H} NMR spectrum of H-PEtG-MMT (CDCl3, 100 MHz)

Figure A1.21. 13C {1H} NMR spectrum of L-PGAm-T (D2O, 150 MHz)
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Figure A1.22. 13C {1H} NMR spectrum of L-PGAm-MMT (D2O, 100 MHz)

Figure A1.23. 13C {1H} NMR spectrum of L-PGAm-BOM (D2O, 100 MHz)
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Figure A1.24. 13C {1H} NMR spectrum of H-PGAm-T (D2O, 100 MHz)

Figure A1.25. 13C {1H} NMR spectrum of H-PGAm-MMT (D2O, 100 MHz)
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Figure A1.26.

13

C {1H} NMR spectrum of L-PGAm-DTPA-T (D2O, 100 MHz). Due to having

such a bulky molecule, the backbone peak required a recycle delay of 30 s with 1024 scans,
resulting in a total acquisition time of just over 8.5 h. Due to complications associated with
performing longer NMR scans, it was determined that the small signal from the backbone (~94
ppm) was adequate.
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Figure A1.27.

13

C {1H} NMR spectrum of L-PGAm-DTPA-BOM (D2O, 150 MHz). Due to

having such a bulky molecule, the backbone peak required a recycle delay of 30 s with 1024 scans,
resulting in a total acquisition time of just over 8.5 h. Due to complications associated with
performing longer NMR scans, it was determined that the small signal from the backbone (~95
ppm) was adequate.
As discussed in the main text, the degradation speed of the final MMT capped polymer was still
quite rapid, requiring only ~8 h to fully degrade. For this reason, it was impossible to obtain an
adequate 13C NMR spectrum of this product. Due to the similarities in all synthesis procedures and
other characterization data, there is still high confidence that the MMT product was functionalized
as expected.
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Figure A1.28. 13C {1H} NMR spectrum of H-PGAm-DTPA-T (D2O, 100 MHz). Due to having
such a bulky molecule, the backbone peak required a recycle delay of 30 s with 1024 scans,
resulting in a total acquisition time of just over 8.5 h. Due to complications associated with
performing longer NMR scans, it was determined that the small signal from the backbone (~95
ppm) was adequate.
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DLS Distributions

Figure A1.29. DLS volume of distributions of PGAm-DTPA-T when prepared with varying
amounts of DTPA (20, 40, 80 equivalents.). Little to no difference was observed in the volume
distribution, allowing for a less wasteful, more optimal synthesis route.
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FT-IR Spectra

Figure A1.30. Stacked FT-IR spectra of the various synthesized low-weight trityl-capped
polymers.

Figure A1.31. Stacked FT-IR spectra of the various synthesized low-weight MMT-capped
polymers.
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Figure A1.32. Stacked FT-IR spectra of the various synthesized BOM-capped polymers.

Figure A1.33. Stacked FT-IR spectra of the various synthesized high-weight trityl-capped
polymers.
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Figure A1.34. Stacked FT-IR spectra of the various synthesized high-weight MMT-capped
polymers.

Size-Exclusion Chromatograms

Figure A1.35. Overlay of size-exclusion chromatograms of the different end capped PEtGs.
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Degradation Studies:

Figure A1.36. Depolymerization of L-PGAm-DTPA-T in deuterated PBS (1×) monitored by 1H
NMR (600 MHz). The blue star indicates the deuterated solvent that the spectra was taken in.

Figure A1.37. Depolymerization of L-PGAm-DTPA-MMT in deuterated PBS (1×) monitored by
1

H NMR (600 MHz). The blue star indicates the deuterated solvent that the spectra was taken in.
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Figure A1.38. Depolymerization of L-PGAm-DTPA-BOM in deuterated PBS (1×) monitored by
1

H NMR (600 MHz). The blue star indicates the deuterated solvent that the spectra was taken in.

Figure A1.39. Depolymerization of H-PGAm-DTPA-MMT in deuterated PBS (1×) monitored by
1

H NMR (600 MHz). The blue star indicates the deuterated solvent that the spectra was taken in.
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Metal Content Determination of the Contrast Agent by Micro-CT

Figure A1.40. A) Micro-CT image (at 120 kVp) of a phantom with calibration standards
containing known concentrations of gadolinium chloride, which were used to determine the
gadolinium content of the high-concentration L-PGAm-DTPA-Gd-T, L-PGAm-DTPA-Gd-MMT,
H-PGAm-DTPA-Gd-T and H-PGAm-DTPA-Gd-MMT. B) Measured CT number as a function of
gadolinium concentration. The CT numbers gave insight to the maximum gadolinium
concentration and was in agreeance with ICP-ms results.
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In vivo Toxicity
All mice were weighed consistently as monitoring/imaging progressed to ensure animal health was
being prioritized.

Figure A1.41. Normalized weight loss values over time for mice injected with H-PGAm-DTPAGd-T and H-PGAm-DTPA-Gd-MMT. No mice died over the 4-week period and none had more
than 10% weight loss.
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Appendix 2: Chapter 3 Supplementary Figures
1

H NMR Spectra (for Characterization)

Figure A2.1: 1H NMR spectrum of PEG113-N3 (CDCl3, 400 MHz)
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Figure A2.2: 1H NMR spectrum of PEtG-AT (CDCl3, 400 MHz)

Figure A2.3: 1H NMR spectrum of PEtG-AMT (CDCl3, 400 MHz)
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Figure A2.4: 1H NMR spectrum of PEtG-AT-PEG (CDCl 3, 400 MHz)

Figure A2.5: 1H NMR spectrum of PEtG-AMT-PEG (CDCl 3, 400 MHz)

123

13

C {1H} NMR Spectra (for Characterization)

Figure A2.6: 13C {1H} NMR spectrum of PEG113-N3 (CDCl3, 100 MHz)

Figure A2.7: 13C {1H} NMR spectrum of PEtG-AT (CDCl3, 100 MHz)
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Figure A2.8: 13C {1H} NMR spectrum of PEtG-AMT (CDCl 3, 100 MHz)

Figure A2.9: 13C {1H} NMR spectrum of PEtG-AT-PEG (CDCl 3, 100 MHz). The green star
indicates the new peak from the PEG.

125

Figure A2.10: 13C {1H} NMR spectrum of PEtG-AMT-PEG (CDCl3, 100 MHz). The green star
indicates the new peak from the PEG.
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FT-IR Spectra

Figure A2.11: FT-IR spectra of various synthesized polymers, PEG113-N3, PEtG-AMT, PEtGAMT-PEG.

TGA Trace

Figure A2.12: TGA trace of oleate-coated GdNPs

127

DLS Size Distributions

Figure A2.13: DLS volume size distribution of empty PEtG-AT-PEG micelle
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Appendix 3: Animal Use Protocol Renewal Approval
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Appendix 4: Permission to Reuse Copyrighted Material
Figure 1.1

Figure 1.2
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Figure 1.3

Figure 1.7
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Figure 1.10

Figure 1.12
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Figure 1.13
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